Armda的个人主页 - 老虎社区

Armda

暂无个人介绍

IP属地：未知

2关注

4粉丝

0主题

0勋章

2021-12-22

WHO recommends 4th dose of vaccination

Dec 21 (Reuters) - Novavax said on Tuesday the World Health Organization's (WHO) panel of experts had recommended a third dose of its vaccine, NVX-CoV2373, for immunocompromised persons.The WHO's Strategic Advisory Group of Experts on Immunization, known as SAGE, issued a series of recommendations, including the use of the vaccine in persons with comorbidities, breastfeeding women, and those living with HIV.After reviewing Novavax data the independent experts said the vaccine could be used in pregnant women if the benefits of vaccination to the pregnant woman outweigh the potential risks.On Friday, the WHO issued an emergency use listing to Novavax's vaccine made by the Serum Institute of India, the world's biggest vaccine maker, paving the way for its use in low- and middle-income countri

WHO recommends 4th dose of vaccination

2021-12-22

Novavax (NVAX) is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck."We will be filing within the next few days in the U.S.," Erck told Yahoo Finance Live on Tuesday.The company has made significant progress on its path to its first commercial product, the two-dose COVID-19 vaccine, marking three major milestones in the past week.Novavax has now received four emergency use approvals, including a listing from the World Health Organization, making it the ninth vaccine authorized by the agency, as well as conditional marketing in the European Union. In addition, the company announced administering its first dose in Indonesia Tuesday, where it recently received emergency use authorizat

2021-12-22

Novavax (NVAX) is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck."We will be filing within the next few days in the U.S.," Erck told Yahoo Finance Live on Tuesday.The company has made significant progress on its path to its first commercial product, the two-dose COVID-19 vaccine, marking three major milestones in the past week.Novavax has now received four emergency use approvals, including a listing from the World Health Organization, making it the ninth vaccine authorized by the agency, as well as conditional marketing in the European Union. In addition, the company announced administering its first dose in Indonesia Tuesday, where it recently received emergency use authorizat

2021-12-17

😊

Nasdaq ends sharply lower as investors dump growth stocks

2021-12-15

thanks

Over 25% Of Nio Option Flows Are Expiring Friday: Will It Bounce?

2021-12-10

thanks

Wall St closes lower ahead of inflation data, Fed meeting

2021-12-07

thanks

Vaccine Stocks: Why MRNA, BNTX, NVAX, PFE Stocks Are Stumbling Today

2021-11-23

go go go!!

Can Apple Close Above The All-Time Highs This Week? Option Analysis

2021-11-22

yeah

Why Elon Musk’s Tesla Stock Sales Are a Non-Event

2021-11-20

wa...

抱歉，原内容已删除

2021-11-19

grats

Longeveron continued to climb over 50% in premarket trading as FDA approved its Lomecel-B for rare pediatric disease designation

2021-11-17

nice

Tesla shares rose 1.4% in premarket trading

2021-11-17

thanks!!

抱歉，原内容已删除

2021-11-16

oh no....

Tesla stock falls 1.4% premarket, heads toward 4th-straight loss and 7th loss in 8 days

2021-11-15

yeah!!

抱歉，原内容已删除

2021-11-15

okies

4 Stocks Insiders Are Selling

2021-11-15

yeah

抱歉，原内容已删除

2021-11-15

oh no

抱歉，原内容已删除

2021-11-13

Like!!

Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4098771492575270","uuid":"4098771492575270","gmtCreate":1635669443212,"gmtModify":1635669443212,"name":"Armda","pinyin":"armda","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":2,"tweetSize":19,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.07","exceedPercentage":"60.51%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":691953728,"gmtCreate":1640129700173,"gmtModify":1640138818666,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"title":"WHO recommends 4th dose of vaccination","htmlText":"Dec 21 (Reuters) - Novavax said on Tuesday the World Health Organization's (WHO) panel of experts had recommended a third dose of its vaccine, NVX-CoV2373, for immunocompromised persons.The WHO's Strategic Advisory Group of Experts on Immunization, known as SAGE, issued a series of recommendations, including the use of the vaccine in persons with comorbidities, breastfeeding women, and those living with HIV.After reviewing Novavax data the independent experts said the vaccine could be used in pregnant women if the benefits of vaccination to the pregnant woman outweigh the potential risks.On Friday, the WHO issued an emergency use listing to Novavax's vaccine made by the Serum Institute of India, the world's biggest vaccine maker, paving the way for its use in low- and middle-income countri","listText":"Dec 21 (Reuters) - Novavax said on Tuesday the World Health Organization's (WHO) panel of experts had recommended a third dose of its vaccine, NVX-CoV2373, for immunocompromised persons.The WHO's Strategic Advisory Group of Experts on Immunization, known as SAGE, issued a series of recommendations, including the use of the vaccine in persons with comorbidities, breastfeeding women, and those living with HIV.After reviewing Novavax data the independent experts said the vaccine could be used in pregnant women if the benefits of vaccination to the pregnant woman outweigh the potential risks.On Friday, the WHO issued an emergency use listing to Novavax's vaccine made by the Serum Institute of India, the world's biggest vaccine maker, paving the way for its use in low- and middle-income countri","text":"Dec 21 (Reuters) - Novavax said on Tuesday the World Health Organization's (WHO) panel of experts had recommended a third dose of its vaccine, NVX-CoV2373, for immunocompromised persons.The WHO's Strategic Advisory Group of Experts on Immunization, known as SAGE, issued a series of recommendations, including the use of the vaccine in persons with comorbidities, breastfeeding women, and those living with HIV.After reviewing Novavax data the independent experts said the vaccine could be used in pregnant women if the benefits of vaccination to the pregnant woman outweigh the potential risks.On Friday, the WHO issued an emergency use listing to Novavax's vaccine made by the Serum Institute of India, the world's biggest vaccine maker, paving the way for its use in low- and middle-income countri","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":5,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/691953728","isVote":1,"tweetType":1,"viewCount":2003,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000408","authorId":"9000000000000408","name":"RodBeard","avatar":"https://static.tigerbbs.com/af002b44e35ebf40cafbbaf194de9c06","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"9000000000000408","idStr":"9000000000000408"},"content":"This is important for the global economic recovery in 2022.","text":"This is important for the global economic recovery in 2022.","html":"This is important for the global economic recovery in 2022."}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691950560,"gmtCreate":1640129527524,"gmtModify":1640138892313,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"Novavax (NVAX) is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck.\"We will be filing within the next few days in the U.S.,\" Erck told Yahoo Finance Live on Tuesday.The company has made significant progress on its path to its first commercial product, the two-dose COVID-19 vaccine, marking three major milestones in the past week.Novavax has now received four emergency use approvals, including a listing from the World Health Organization, making it the ninth vaccine authorized by the agency, as well as conditional marketing in the European Union. In addition, the company announced administering its first dose in Indonesia Tuesday, where it recently received emergency use authorizat","listText":"Novavax (NVAX) is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck.\"We will be filing within the next few days in the U.S.,\" Erck told Yahoo Finance Live on Tuesday.The company has made significant progress on its path to its first commercial product, the two-dose COVID-19 vaccine, marking three major milestones in the past week.Novavax has now received four emergency use approvals, including a listing from the World Health Organization, making it the ninth vaccine authorized by the agency, as well as conditional marketing in the European Union. In addition, the company announced administering its first dose in Indonesia Tuesday, where it recently received emergency use authorizat","text":"Novavax (NVAX) is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck.\"We will be filing within the next few days in the U.S.,\" Erck told Yahoo Finance Live on Tuesday.The company has made significant progress on its path to its first commercial product, the two-dose COVID-19 vaccine, marking three major milestones in the past week.Novavax has now received four emergency use approvals, including a listing from the World Health Organization, making it the ninth vaccine authorized by the agency, as well as conditional marketing in the European Union. In addition, the company announced administering its first dose in Indonesia Tuesday, where it recently received emergency use authorizat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/691950560","isVote":1,"tweetType":1,"viewCount":2821,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000408","authorId":"9000000000000408","name":"RodBeard","avatar":"https://static.tigerbbs.com/af002b44e35ebf40cafbbaf194de9c06","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"9000000000000408","idStr":"9000000000000408"},"content":"Novavax is a great company. However, with the gradual weakening of the epidemic, we should not buy or hold the shares of this company now.","text":"Novavax is a great company. However, with the gradual weakening of the epidemic, we should not buy or hold the shares of this company now.","html":"Novavax is a great company. However, with the gradual weakening of the epidemic, we should not buy or hold the shares of this company now."}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691927406,"gmtCreate":1640129487937,"gmtModify":1640138964321,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"Novavax (NVAX) is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck.\"We will be filing within the next few days in the U.S.,\" Erck told Yahoo Finance Live on Tuesday.The company has made significant progress on its path to its first commercial product, the two-dose COVID-19 vaccine, marking three major milestones in the past week.Novavax has now received four emergency use approvals, including a listing from the World Health Organization, making it the ninth vaccine authorized by the agency, as well as conditional marketing in the European Union. In addition, the company announced administering its first dose in Indonesia Tuesday, where it recently received emergency use authorizat","listText":"Novavax (NVAX) is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck.\"We will be filing within the next few days in the U.S.,\" Erck told Yahoo Finance Live on Tuesday.The company has made significant progress on its path to its first commercial product, the two-dose COVID-19 vaccine, marking three major milestones in the past week.Novavax has now received four emergency use approvals, including a listing from the World Health Organization, making it the ninth vaccine authorized by the agency, as well as conditional marketing in the European Union. In addition, the company announced administering its first dose in Indonesia Tuesday, where it recently received emergency use authorizat","text":"Novavax (NVAX) is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck.\"We will be filing within the next few days in the U.S.,\" Erck told Yahoo Finance Live on Tuesday.The company has made significant progress on its path to its first commercial product, the two-dose COVID-19 vaccine, marking three major milestones in the past week.Novavax has now received four emergency use approvals, including a listing from the World Health Organization, making it the ninth vaccine authorized by the agency, as well as conditional marketing in the European Union. In addition, the company announced administering its first dose in Indonesia Tuesday, where it recently received emergency use authorizat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/691927406","isVote":1,"tweetType":1,"viewCount":2426,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000408","authorId":"9000000000000408","name":"RodBeard","avatar":"https://static.tigerbbs.com/af002b44e35ebf40cafbbaf194de9c06","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"9000000000000408","idStr":"9000000000000408"},"content":"Novavax is a great company. However, with the gradual weakening of the epidemic, we should not buy or hold the shares of this company now.","text":"Novavax is a great company. However, with the gradual weakening of the epidemic, we should not buy or hold the shares of this company now.","html":"Novavax is a great company. However, with the gradual weakening of the epidemic, we should not buy or hold the shares of this company now."}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690480691,"gmtCreate":1639701311917,"gmtModify":1639701311996,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"😊&nbsp;","listText":"😊&nbsp;","text":"😊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690480691","repostId":"2192920942","repostType":2,"repost":{"id":"2192920942","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639694745,"share":"https://www.laohu8.com/m/news/2192920942?lang=&edition=full","pubTime":"2021-12-17 06:45","market":"us","language":"en","title":"Nasdaq ends sharply lower as investors dump growth stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2192920942","media":"Reuters","summary":"* Fed to end bond purchases, signals rate hikes in 2022\n* Tech is worst among 11 S&P 500 sector inde","content":"<p>* Fed to end bond purchases, signals rate hikes in 2022</p>\n<p>* Tech is worst among 11 S&amp;P 500 sector indexes, financials rally</p>\n<p>* Lennar slips after missing quarterly profit</p>\n<p>* Indexes: Dow -0.08%, S&amp;P 500 -0.87%, Nasdaq -2.47%</p>\n<p>Dec 16 (Reuters) - The Nasdaq ended sharply lower on Thursday as the Federal Reserve's announcement of a faster end to its pandemic-era stimulus pushed investors away from Big Tech and toward more economically sensitive sectors.</p>\n<p>Nvidia,Apple,Microsoft, Amazon&nbsp;and Tesla&nbsp;tumbled between 2.6% and 6.8%, hitting the Nasdaq&nbsp;and the S&amp;P 500, while the Dow Jones Industrial Average declined marginally.</p>\n<p>Most of those heavyweight growth stocks have outperformed the broader market in 2021, with Nvidia up more than 100% year to date.</p>\n<p>The Dow Jones Industrial Average&nbsp;fell 0.08% to end at 35,897.64, while the S&amp;P 500&nbsp;lost 0.87% to 4,668.67.</p>\n<p>The Nasdaq Composite&nbsp;dropped 2.47% to 15,180.44.</p>\n<p>The U.S. central bank said on Wednesday it would end its bond purchases in March and signaled three quarter-percentage-point interest rate hikes by the end of 2022.</p>\n<p>That pleased investors who have increasingly worried about an inflation spike related to the coronavirus pandemic. But on Thursday it contributed to the sell-off in growth stocks.</p>\n<p>The S&amp;P 500 value index&nbsp;climbed 0.7%, while the growth index fell 2.1%, reflecting investors' views that high-growth stocks tend to underperform when interest rates rise. The value index includes stocks seen as more likely to do well during an economic recovery.</p>\n<p>\"You're seeing money come out of growth, as it should. If we are going into an environment where interest rates are going up, growth stocks are going to be less attractive\" said Dennis Dick, a trader at Bright Trading LLC.</p>\n<p>\"There's a lot of uncertainty as we go into 2022... We're going to have a more hawkish Fed that is going to pull away the punch bowl,\" he said.</p>\n<p>Among the 11 major S&amp;P 500 sector indexes, technology&nbsp;slumped 2.9%, while financials&nbsp;rallied 1.2%. Eight of the sectors gained, even as the overall index fell.</p>\n<p>\"The Fed gave the market what it wanted, and today I think investors are turning again to pandemic uncertainty, and they're also cautious going into the end of the year,\" said Lindsey Bell, chief investment strategist at Ally Invest, in Charlotte, North Carolina.</p>\n<p>Recent readings on surging producer and consumer prices, as well as the fast-spreading Omicron variant of the coronavirus, have fueled anxiety. The S&amp;P 500, nonetheless, remains up about 25% in 2021 and it is trading near record highs.</p>\n<p>The CBOE Volatility index, often considered Wall Street's fear gauge, slipped to a three-week low.</p>\n<p>Data showed the number of Americans filing new claims for unemployment benefits increased moderately last week, remaining at levels consistent with tightening labor market conditions.</p>\n<p>Separately, a survey showed production at U.S. factories increased to the highest level in nearly three years in November.</p>\n<p>Lennar Corp&nbsp;fell 4.1% after the homebuilder missed analysts' estimates for quarterly profit as pandemic-led supply chain issues pushed lumber costs higher and delayed house deliveries.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.03-to-1 ratio; on Nasdaq, a 1.93-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 69 new 52-week highs and 3 new lows; the Nasdaq Composite recorded 43 new highs and 184 new lows.</p>\n<p>Volume on U.S. exchanges was 11.6 billion shares, in line with the average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq ends sharply lower as investors dump growth stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq ends sharply lower as investors dump growth stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-17 06:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Fed to end bond purchases, signals rate hikes in 2022</p>\n<p>* Tech is worst among 11 S&amp;P 500 sector indexes, financials rally</p>\n<p>* Lennar slips after missing quarterly profit</p>\n<p>* Indexes: Dow -0.08%, S&amp;P 500 -0.87%, Nasdaq -2.47%</p>\n<p>Dec 16 (Reuters) - The Nasdaq ended sharply lower on Thursday as the Federal Reserve's announcement of a faster end to its pandemic-era stimulus pushed investors away from Big Tech and toward more economically sensitive sectors.</p>\n<p>Nvidia,Apple,Microsoft, Amazon&nbsp;and Tesla&nbsp;tumbled between 2.6% and 6.8%, hitting the Nasdaq&nbsp;and the S&amp;P 500, while the Dow Jones Industrial Average declined marginally.</p>\n<p>Most of those heavyweight growth stocks have outperformed the broader market in 2021, with Nvidia up more than 100% year to date.</p>\n<p>The Dow Jones Industrial Average&nbsp;fell 0.08% to end at 35,897.64, while the S&amp;P 500&nbsp;lost 0.87% to 4,668.67.</p>\n<p>The Nasdaq Composite&nbsp;dropped 2.47% to 15,180.44.</p>\n<p>The U.S. central bank said on Wednesday it would end its bond purchases in March and signaled three quarter-percentage-point interest rate hikes by the end of 2022.</p>\n<p>That pleased investors who have increasingly worried about an inflation spike related to the coronavirus pandemic. But on Thursday it contributed to the sell-off in growth stocks.</p>\n<p>The S&amp;P 500 value index&nbsp;climbed 0.7%, while the growth index fell 2.1%, reflecting investors' views that high-growth stocks tend to underperform when interest rates rise. The value index includes stocks seen as more likely to do well during an economic recovery.</p>\n<p>\"You're seeing money come out of growth, as it should. If we are going into an environment where interest rates are going up, growth stocks are going to be less attractive\" said Dennis Dick, a trader at Bright Trading LLC.</p>\n<p>\"There's a lot of uncertainty as we go into 2022... We're going to have a more hawkish Fed that is going to pull away the punch bowl,\" he said.</p>\n<p>Among the 11 major S&amp;P 500 sector indexes, technology&nbsp;slumped 2.9%, while financials&nbsp;rallied 1.2%. Eight of the sectors gained, even as the overall index fell.</p>\n<p>\"The Fed gave the market what it wanted, and today I think investors are turning again to pandemic uncertainty, and they're also cautious going into the end of the year,\" said Lindsey Bell, chief investment strategist at Ally Invest, in Charlotte, North Carolina.</p>\n<p>Recent readings on surging producer and consumer prices, as well as the fast-spreading Omicron variant of the coronavirus, have fueled anxiety. The S&amp;P 500, nonetheless, remains up about 25% in 2021 and it is trading near record highs.</p>\n<p>The CBOE Volatility index, often considered Wall Street's fear gauge, slipped to a three-week low.</p>\n<p>Data showed the number of Americans filing new claims for unemployment benefits increased moderately last week, remaining at levels consistent with tightening labor market conditions.</p>\n<p>Separately, a survey showed production at U.S. factories increased to the highest level in nearly three years in November.</p>\n<p>Lennar Corp&nbsp;fell 4.1% after the homebuilder missed analysts' estimates for quarterly profit as pandemic-led supply chain issues pushed lumber costs higher and delayed house deliveries.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.03-to-1 ratio; on Nasdaq, a 1.93-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 69 new 52-week highs and 3 new lows; the Nasdaq Composite recorded 43 new highs and 184 new lows.</p>\n<p>Volume on U.S. exchanges was 11.6 billion shares, in line with the average over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SSO":"两倍做多标普500ETF","BK4099":"汽车制造商","TSLA":"特斯拉","BK4549":"软银资本持仓","BK4088":"住宅建筑","BK4548":"巴美列捷福持仓","NVDA":"英伟达","SPXU":"三倍做空标普500ETF","SQQQ":"纳指三倍做空ETF","AMZN":"亚马逊","BK4515":"5G概念","BK4554":"元宇宙及AR概念","SDOW":"道指三倍做空ETF-ProShares","OEF":"标普100指数ETF-iShares","BK4553":"喜马拉雅资本持仓","QQQ":"纳指100ETF","DXD":"道指两倍做空ETF","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","LEN":"莱纳建筑公司","SDS":"两倍做空标普500ETF","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4524":"宅经济概念","BK4501":"段永平概念","BK4543":"AI","BK4538":"云计算","BK4527":"明星科技股","DDM":"道指两倍做多ETF","BK4559":"巴菲特持仓","TQQQ":"纳指三倍做多ETF",".DJI":"道琼斯","UDOW":"道指三倍做多ETF-ProShares","BK4503":"景林资产持仓","SH":"标普500反向ETF","IVV":"标普500指数ETF",".IXIC":"NASDAQ Composite","BK4551":"寇图资本持仓","DOG":"道指反向ETF","BK4504":"桥水持仓","OEX":"标普100",".SPX":"S&P 500 Index","BK4505":"高瓴资本持仓","PSQ":"纳指反向ETF","BK4561":"索罗斯持仓","UPRO":"三倍做多标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192920942","content_text":"* Fed to end bond purchases, signals rate hikes in 2022\n* Tech is worst among 11 S&P 500 sector indexes, financials rally\n* Lennar slips after missing quarterly profit\n* Indexes: Dow -0.08%, S&P 500 -0.87%, Nasdaq -2.47%\nDec 16 (Reuters) - The Nasdaq ended sharply lower on Thursday as the Federal Reserve's announcement of a faster end to its pandemic-era stimulus pushed investors away from Big Tech and toward more economically sensitive sectors.\nNvidia,Apple,Microsoft, Amazon and Tesla tumbled between 2.6% and 6.8%, hitting the Nasdaq and the S&P 500, while the Dow Jones Industrial Average declined marginally.\nMost of those heavyweight growth stocks have outperformed the broader market in 2021, with Nvidia up more than 100% year to date.\nThe Dow Jones Industrial Average fell 0.08% to end at 35,897.64, while the S&P 500 lost 0.87% to 4,668.67.\nThe Nasdaq Composite dropped 2.47% to 15,180.44.\nThe U.S. central bank said on Wednesday it would end its bond purchases in March and signaled three quarter-percentage-point interest rate hikes by the end of 2022.\nThat pleased investors who have increasingly worried about an inflation spike related to the coronavirus pandemic. But on Thursday it contributed to the sell-off in growth stocks.\nThe S&P 500 value index climbed 0.7%, while the growth index fell 2.1%, reflecting investors' views that high-growth stocks tend to underperform when interest rates rise. The value index includes stocks seen as more likely to do well during an economic recovery.\n\"You're seeing money come out of growth, as it should. If we are going into an environment where interest rates are going up, growth stocks are going to be less attractive\" said Dennis Dick, a trader at Bright Trading LLC.\n\"There's a lot of uncertainty as we go into 2022... We're going to have a more hawkish Fed that is going to pull away the punch bowl,\" he said.\nAmong the 11 major S&P 500 sector indexes, technology slumped 2.9%, while financials rallied 1.2%. Eight of the sectors gained, even as the overall index fell.\n\"The Fed gave the market what it wanted, and today I think investors are turning again to pandemic uncertainty, and they're also cautious going into the end of the year,\" said Lindsey Bell, chief investment strategist at Ally Invest, in Charlotte, North Carolina.\nRecent readings on surging producer and consumer prices, as well as the fast-spreading Omicron variant of the coronavirus, have fueled anxiety. The S&P 500, nonetheless, remains up about 25% in 2021 and it is trading near record highs.\nThe CBOE Volatility index, often considered Wall Street's fear gauge, slipped to a three-week low.\nData showed the number of Americans filing new claims for unemployment benefits increased moderately last week, remaining at levels consistent with tightening labor market conditions.\nSeparately, a survey showed production at U.S. factories increased to the highest level in nearly three years in November.\nLennar Corp fell 4.1% after the homebuilder missed analysts' estimates for quarterly profit as pandemic-led supply chain issues pushed lumber costs higher and delayed house deliveries.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.03-to-1 ratio; on Nasdaq, a 1.93-to-1 ratio favored decliners.\nThe S&P 500 posted 69 new 52-week highs and 3 new lows; the Nasdaq Composite recorded 43 new highs and 184 new lows.\nVolume on U.S. exchanges was 11.6 billion shares, in line with the average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":983,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607252295,"gmtCreate":1639551364321,"gmtModify":1639551395541,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"thanks","listText":"thanks","text":"thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607252295","repostId":"1127951705","repostType":2,"repost":{"id":"1127951705","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1639527737,"share":"https://www.laohu8.com/m/news/1127951705?lang=&edition=full","pubTime":"2021-12-15 08:22","market":"us","language":"en","title":"Over 25% Of Nio Option Flows Are Expiring Friday: Will It Bounce?","url":"https://stock-news.laohu8.com/highlight/detail?id=1127951705","media":"Benzinga","summary":"What Happened:Shares of NIO Inc lost 4% Tuesday as many U.S. and Asian stocks fell due to omicron CO","content":"<p><b>What Happened:</b>Shares of&nbsp;<b>NIO Inc</b>&nbsp;lost 4% Tuesday&nbsp;as many U.S. and Asian stocks fell due to omicron COVID-19 variant concerns.</p>\n<p>The stock is approaching a major support level around $30 that has held since October of 2020.&nbsp;Looking at the option flows on the day, there are over 148,000 calls and 71,000 puts, so two out of every three&nbsp;options&nbsp;on the day are calls (image below).</p>\n<p>Prior to Tuesday's trading, there were approximately 1.8 million calls and 1.6 million puts in NIO for a total of 3.48 million options.</p>\n<p><img src=\"https://static.tigerbbs.com/1829707a572d0f5331bc22fb8bb77d2e\" tg-width=\"1023\" tg-height=\"279\" width=\"100%\" height=\"auto\"></p>\n<p>This means that the option flows for Tuesday&nbsp;represent about 7% of the total options, which is solid considering the FOMC meeting on Wednesday, Dec. 15 is putting a damper on flows.</p>\n<p><b>Why It Matters:</b>Generally traders do not make aggressive bets ahead of a&nbsp;FOMC, meeting, especially the last one of the year, which could set the tone for trading in 2022.</p>\n<p>Of the approximately 219,000 options traded today, only about 60,000 of them are short dated (expiring Friday, Dec. 17), which means the majority of flows are forward looking beyond the FOMC and monthly op-ex.</p>\n<p>The next largest option expiry by volume is the Jan.&nbsp;21 op-ex, which means a strong amount of traders are taking bullish bets on Nio&nbsp;into next year.</p>\n<p><b>What's Next:</b>Looking at the option chain for the Jan. 21 expiry next year, the largest strikes by volume are concentrated between the $35 and $40 strikes (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/747fa367be175f2627d9a91fd7542fac\" tg-width=\"1117\" tg-height=\"399\" width=\"100%\" height=\"auto\"></p>\n<p>Meanwhile, the largest strikes by open interest are the $40 and $45 strikes, which shows a fair amount of interest for a bounce off support and a move back up into the $40s.</p>\n<p>It should be noted the option market is currently pricing in a 14% probability NIO closes at or above $40 by the January op-ex next year, so it's currently a lower probability event.</p>\n<p>But if the $30 level can hold for this week&nbsp;and there is no hawkishness out of the Fed for the FOMC on Dec. 15, then equities might get a Christmas rally to end the year, as the bearish pressure leading into the FOMC could subside.</p>\n<p>On the other hand, if the stock closes below the $30 level on a weekly closing basis, then the next support does not come in until&nbsp;around $25.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Over 25% Of Nio Option Flows Are Expiring Friday: Will It Bounce?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOver 25% Of Nio Option Flows Are Expiring Friday: Will It Bounce?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-15 08:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>What Happened:</b>Shares of&nbsp;<b>NIO Inc</b>&nbsp;lost 4% Tuesday&nbsp;as many U.S. and Asian stocks fell due to omicron COVID-19 variant concerns.</p>\n<p>The stock is approaching a major support level around $30 that has held since October of 2020.&nbsp;Looking at the option flows on the day, there are over 148,000 calls and 71,000 puts, so two out of every three&nbsp;options&nbsp;on the day are calls (image below).</p>\n<p>Prior to Tuesday's trading, there were approximately 1.8 million calls and 1.6 million puts in NIO for a total of 3.48 million options.</p>\n<p><img src=\"https://static.tigerbbs.com/1829707a572d0f5331bc22fb8bb77d2e\" tg-width=\"1023\" tg-height=\"279\" width=\"100%\" height=\"auto\"></p>\n<p>This means that the option flows for Tuesday&nbsp;represent about 7% of the total options, which is solid considering the FOMC meeting on Wednesday, Dec. 15 is putting a damper on flows.</p>\n<p><b>Why It Matters:</b>Generally traders do not make aggressive bets ahead of a&nbsp;FOMC, meeting, especially the last one of the year, which could set the tone for trading in 2022.</p>\n<p>Of the approximately 219,000 options traded today, only about 60,000 of them are short dated (expiring Friday, Dec. 17), which means the majority of flows are forward looking beyond the FOMC and monthly op-ex.</p>\n<p>The next largest option expiry by volume is the Jan.&nbsp;21 op-ex, which means a strong amount of traders are taking bullish bets on Nio&nbsp;into next year.</p>\n<p><b>What's Next:</b>Looking at the option chain for the Jan. 21 expiry next year, the largest strikes by volume are concentrated between the $35 and $40 strikes (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/747fa367be175f2627d9a91fd7542fac\" tg-width=\"1117\" tg-height=\"399\" width=\"100%\" height=\"auto\"></p>\n<p>Meanwhile, the largest strikes by open interest are the $40 and $45 strikes, which shows a fair amount of interest for a bounce off support and a move back up into the $40s.</p>\n<p>It should be noted the option market is currently pricing in a 14% probability NIO closes at or above $40 by the January op-ex next year, so it's currently a lower probability event.</p>\n<p>But if the $30 level can hold for this week&nbsp;and there is no hawkishness out of the Fed for the FOMC on Dec. 15, then equities might get a Christmas rally to end the year, as the bearish pressure leading into the FOMC could subside.</p>\n<p>On the other hand, if the stock closes below the $30 level on a weekly closing basis, then the next support does not come in until&nbsp;around $25.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127951705","content_text":"What Happened:Shares of NIO Inc lost 4% Tuesday as many U.S. and Asian stocks fell due to omicron COVID-19 variant concerns.\nThe stock is approaching a major support level around $30 that has held since October of 2020. Looking at the option flows on the day, there are over 148,000 calls and 71,000 puts, so two out of every three options on the day are calls (image below).\nPrior to Tuesday's trading, there were approximately 1.8 million calls and 1.6 million puts in NIO for a total of 3.48 million options.\n\nThis means that the option flows for Tuesday represent about 7% of the total options, which is solid considering the FOMC meeting on Wednesday, Dec. 15 is putting a damper on flows.\nWhy It Matters:Generally traders do not make aggressive bets ahead of a FOMC, meeting, especially the last one of the year, which could set the tone for trading in 2022.\nOf the approximately 219,000 options traded today, only about 60,000 of them are short dated (expiring Friday, Dec. 17), which means the majority of flows are forward looking beyond the FOMC and monthly op-ex.\nThe next largest option expiry by volume is the Jan. 21 op-ex, which means a strong amount of traders are taking bullish bets on Nio into next year.\nWhat's Next:Looking at the option chain for the Jan. 21 expiry next year, the largest strikes by volume are concentrated between the $35 and $40 strikes (image below).\n\nMeanwhile, the largest strikes by open interest are the $40 and $45 strikes, which shows a fair amount of interest for a bounce off support and a move back up into the $40s.\nIt should be noted the option market is currently pricing in a 14% probability NIO closes at or above $40 by the January op-ex next year, so it's currently a lower probability event.\nBut if the $30 level can hold for this week and there is no hawkishness out of the Fed for the FOMC on Dec. 15, then equities might get a Christmas rally to end the year, as the bearish pressure leading into the FOMC could subside.\nOn the other hand, if the stock closes below the $30 level on a weekly closing basis, then the next support does not come in until around $25.","news_type":1},"isVote":1,"tweetType":1,"viewCount":697,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605095912,"gmtCreate":1639091102229,"gmtModify":1639091102292,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"thanks","listText":"thanks","text":"thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605095912","repostId":"2190964556","repostType":2,"repost":{"id":"2190964556","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639090919,"share":"https://www.laohu8.com/m/news/2190964556?lang=&edition=full","pubTime":"2021-12-10 07:01","market":"us","language":"en","title":"Wall St closes lower ahead of inflation data, Fed meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2190964556","media":"Reuters","summary":"Wall Street closed lower on Thursday as investors banked some profits after three straight days of g","content":"<p>Wall Street closed lower on Thursday as investors banked some profits after three straight days of gains and turned their focus toward upcoming inflation data and how it might influence the Federal Reserve's meeting next week.</p>\n<p>The Nasdaq was down more sharply than the S&amp;P 500 while the Dow was virtually flat, ending down less than 1 point.</p>\n<p>Investors were in a waiting game ahead of U.S. consumer prices index inflation data due Friday morning. A higher-than-expected reading would strengthen the case for a policy tightening decision at the U.S. central bank's meeting.</p>\n<p>In the first three days of the week, the Nasdaq rallied 4.7%, the S&amp;P advanced 3.6% and the Dow gained 3.4% as fears abated about the latest coronavirus variant Omicron.</p>\n<p>\"We had a rip roaring rally. There's still nervous people out there,\" said Dennis Dick, head of markets structure, proprietary trader at Bright Trading LLC in Las Vegas.</p>\n<p>\"We'd a Omicron relief rally but the underlying problem still remains, that the Fed's taking the punchbowl away.\"</p>\n<p>Joe Quinlan, chief market strategist for the CIO office of Bank of America, said investors may be taking profits and pausing buying after the three days of gains.</p>\n<p>\"Also there may be a little risk-off trade ahead of the CPI number on Friday,\" he said. \"If it comes in hotter than expected it really shines the light and the focus on the Fed meeting. The pressure would build on the Fed for a faster tapering.\"</p>\n<p>Fed Chair Powell signaled last week that the meeting would include a discussion about a faster tapering of bond-buying.</p>\n<p>\"It would reaffirm in many people's minds that the Fed is behind the curve,\" said Quinlan.</p>\n<p>If the inflation number implies a need to hike rates faster, this \"would put pressure on technology and give a bid to cyclicals\" he said.</p>\n<p>\"You'd want to buy the companies that could pass on these higher costs to consumers. That undermines the growth story. You want to own more cyclicals and value than growth,\" said Quinlan.</p>\n<p>A Reuters poll of economists predicted the Fed would raise rates by 25 basis points to 0.25-0.50% in the third quarter of next year. However, most saw the risk that a hike comes even sooner.</p>\n<p>The Dow Jones Industrial Average fell 0.06 points to 35,754.69, the S&amp;P 500 lost 33.76 points, or 0.72%, to 4,667.45 and the Nasdaq Composite dropped 269.62 points, or 1.71%, to 15,517.37.</p>\n<p>Nine of the 11 major S&amp;P sectors declined, with consumer discretionary down 1.7%, losing the most and real estate , down 1.4%, and information technology&nbsp;falling 1%, showing the next biggest losses.</p>\n<p>The only sector gainers were healthcare up 0.2% and consumer staples which clung to a 0.06% advance.</p>\n<p>Healthcare was boosted by a CVS Health Corp share gain of 4.5% after the drugstore operator raised its 2021 profit forecast.</p>\n<p>In consumer staples, heavyweight electric car maker Tesla&nbsp;was the biggest percentage decliner, falling 6%.</p>\n<p>Markets have seesawed since late November when the Omicron variant was discovered. Investors worried it could upend a global recovery at a time of surging inflation with Fed commentary exacerbating volatility.</p>\n<p>Wall Street's main indexes were supported this week by an update showing Pfizer and BioNTech's vaccine offered some protection against the Omicron variant.</p>\n<p>Data showed initial claims for state unemployment benefits tumbled 43,000 last week to 184,000, the lowest level in more than 52 years.</p>\n<p>GameStop Corp fell 10% after the video game retailer popular among retail investors said it was issued a subpoena by the U.S. securities regulator back in August for documents on an investigation into its share trading activity.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 3.03-to-1 ratio; on Nasdaq, a 3.05-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 23 new 52-week highs and 1 new lows; the Nasdaq Composite recorded 34 new highs and 68 new lows.</p>\n<p>On U.S. exchanges 9.75 billion shares changed hands compared with the 11.41 billion average for the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St closes lower ahead of inflation data, Fed meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St closes lower ahead of inflation data, Fed meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-10 07:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Wall Street closed lower on Thursday as investors banked some profits after three straight days of gains and turned their focus toward upcoming inflation data and how it might influence the Federal Reserve's meeting next week.</p>\n<p>The Nasdaq was down more sharply than the S&amp;P 500 while the Dow was virtually flat, ending down less than 1 point.</p>\n<p>Investors were in a waiting game ahead of U.S. consumer prices index inflation data due Friday morning. A higher-than-expected reading would strengthen the case for a policy tightening decision at the U.S. central bank's meeting.</p>\n<p>In the first three days of the week, the Nasdaq rallied 4.7%, the S&amp;P advanced 3.6% and the Dow gained 3.4% as fears abated about the latest coronavirus variant Omicron.</p>\n<p>\"We had a rip roaring rally. There's still nervous people out there,\" said Dennis Dick, head of markets structure, proprietary trader at Bright Trading LLC in Las Vegas.</p>\n<p>\"We'd a Omicron relief rally but the underlying problem still remains, that the Fed's taking the punchbowl away.\"</p>\n<p>Joe Quinlan, chief market strategist for the CIO office of Bank of America, said investors may be taking profits and pausing buying after the three days of gains.</p>\n<p>\"Also there may be a little risk-off trade ahead of the CPI number on Friday,\" he said. \"If it comes in hotter than expected it really shines the light and the focus on the Fed meeting. The pressure would build on the Fed for a faster tapering.\"</p>\n<p>Fed Chair Powell signaled last week that the meeting would include a discussion about a faster tapering of bond-buying.</p>\n<p>\"It would reaffirm in many people's minds that the Fed is behind the curve,\" said Quinlan.</p>\n<p>If the inflation number implies a need to hike rates faster, this \"would put pressure on technology and give a bid to cyclicals\" he said.</p>\n<p>\"You'd want to buy the companies that could pass on these higher costs to consumers. That undermines the growth story. You want to own more cyclicals and value than growth,\" said Quinlan.</p>\n<p>A Reuters poll of economists predicted the Fed would raise rates by 25 basis points to 0.25-0.50% in the third quarter of next year. However, most saw the risk that a hike comes even sooner.</p>\n<p>The Dow Jones Industrial Average fell 0.06 points to 35,754.69, the S&amp;P 500 lost 33.76 points, or 0.72%, to 4,667.45 and the Nasdaq Composite dropped 269.62 points, or 1.71%, to 15,517.37.</p>\n<p>Nine of the 11 major S&amp;P sectors declined, with consumer discretionary down 1.7%, losing the most and real estate , down 1.4%, and information technology&nbsp;falling 1%, showing the next biggest losses.</p>\n<p>The only sector gainers were healthcare up 0.2% and consumer staples which clung to a 0.06% advance.</p>\n<p>Healthcare was boosted by a CVS Health Corp share gain of 4.5% after the drugstore operator raised its 2021 profit forecast.</p>\n<p>In consumer staples, heavyweight electric car maker Tesla&nbsp;was the biggest percentage decliner, falling 6%.</p>\n<p>Markets have seesawed since late November when the Omicron variant was discovered. Investors worried it could upend a global recovery at a time of surging inflation with Fed commentary exacerbating volatility.</p>\n<p>Wall Street's main indexes were supported this week by an update showing Pfizer and BioNTech's vaccine offered some protection against the Omicron variant.</p>\n<p>Data showed initial claims for state unemployment benefits tumbled 43,000 last week to 184,000, the lowest level in more than 52 years.</p>\n<p>GameStop Corp fell 10% after the video game retailer popular among retail investors said it was issued a subpoena by the U.S. securities regulator back in August for documents on an investigation into its share trading activity.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 3.03-to-1 ratio; on Nasdaq, a 3.05-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 23 new 52-week highs and 1 new lows; the Nasdaq Composite recorded 34 new highs and 68 new lows.</p>\n<p>On U.S. exchanges 9.75 billion shares changed hands compared with the 11.41 billion average for the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4099":"汽车制造商","TSLA":"特斯拉","BK4548":"巴美列捷福持仓","DJX":"1/100道琼斯","SQQQ":"纳指三倍做空ETF","SDOW":"道指三倍做空ETF-ProShares","QQQ":"纳指100ETF","DXD":"道指两倍做空ETF","BK4534":"瑞士信贷持仓","BK4555":"新能源车","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4196":"保健护理服务","QID":"纳指两倍做空ETF","GME":"游戏驿站","CPI":"IQ Real Return ETF","BK4527":"明星科技股","DDM":"道指两倍做多ETF","CVS":"西维斯健康","TQQQ":"纳指三倍做多ETF","BK4550":"红杉资本持仓",".DJI":"道琼斯","PFE":"辉瑞","BK4076":"电脑与电子产品零售",".IXIC":"NASDAQ Composite","BK4504":"桥水持仓","BK4551":"寇图资本持仓","DOG":"道指反向ETF",".SPX":"S&P 500 Index","BK4547":"WSB热门概念","PSQ":"纳指反向ETF","QLD":"纳指两倍做多ETF","UDOW":"道指三倍做多ETF-ProShares"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190964556","content_text":"Wall Street closed lower on Thursday as investors banked some profits after three straight days of gains and turned their focus toward upcoming inflation data and how it might influence the Federal Reserve's meeting next week.\nThe Nasdaq was down more sharply than the S&P 500 while the Dow was virtually flat, ending down less than 1 point.\nInvestors were in a waiting game ahead of U.S. consumer prices index inflation data due Friday morning. A higher-than-expected reading would strengthen the case for a policy tightening decision at the U.S. central bank's meeting.\nIn the first three days of the week, the Nasdaq rallied 4.7%, the S&P advanced 3.6% and the Dow gained 3.4% as fears abated about the latest coronavirus variant Omicron.\n\"We had a rip roaring rally. There's still nervous people out there,\" said Dennis Dick, head of markets structure, proprietary trader at Bright Trading LLC in Las Vegas.\n\"We'd a Omicron relief rally but the underlying problem still remains, that the Fed's taking the punchbowl away.\"\nJoe Quinlan, chief market strategist for the CIO office of Bank of America, said investors may be taking profits and pausing buying after the three days of gains.\n\"Also there may be a little risk-off trade ahead of the CPI number on Friday,\" he said. \"If it comes in hotter than expected it really shines the light and the focus on the Fed meeting. The pressure would build on the Fed for a faster tapering.\"\nFed Chair Powell signaled last week that the meeting would include a discussion about a faster tapering of bond-buying.\n\"It would reaffirm in many people's minds that the Fed is behind the curve,\" said Quinlan.\nIf the inflation number implies a need to hike rates faster, this \"would put pressure on technology and give a bid to cyclicals\" he said.\n\"You'd want to buy the companies that could pass on these higher costs to consumers. That undermines the growth story. You want to own more cyclicals and value than growth,\" said Quinlan.\nA Reuters poll of economists predicted the Fed would raise rates by 25 basis points to 0.25-0.50% in the third quarter of next year. However, most saw the risk that a hike comes even sooner.\nThe Dow Jones Industrial Average fell 0.06 points to 35,754.69, the S&P 500 lost 33.76 points, or 0.72%, to 4,667.45 and the Nasdaq Composite dropped 269.62 points, or 1.71%, to 15,517.37.\nNine of the 11 major S&P sectors declined, with consumer discretionary down 1.7%, losing the most and real estate , down 1.4%, and information technology falling 1%, showing the next biggest losses.\nThe only sector gainers were healthcare up 0.2% and consumer staples which clung to a 0.06% advance.\nHealthcare was boosted by a CVS Health Corp share gain of 4.5% after the drugstore operator raised its 2021 profit forecast.\nIn consumer staples, heavyweight electric car maker Tesla was the biggest percentage decliner, falling 6%.\nMarkets have seesawed since late November when the Omicron variant was discovered. Investors worried it could upend a global recovery at a time of surging inflation with Fed commentary exacerbating volatility.\nWall Street's main indexes were supported this week by an update showing Pfizer and BioNTech's vaccine offered some protection against the Omicron variant.\nData showed initial claims for state unemployment benefits tumbled 43,000 last week to 184,000, the lowest level in more than 52 years.\nGameStop Corp fell 10% after the video game retailer popular among retail investors said it was issued a subpoena by the U.S. securities regulator back in August for documents on an investigation into its share trading activity.\nDeclining issues outnumbered advancing ones on the NYSE by a 3.03-to-1 ratio; on Nasdaq, a 3.05-to-1 ratio favored decliners.\nThe S&P 500 posted 23 new 52-week highs and 1 new lows; the Nasdaq Composite recorded 34 new highs and 68 new lows.\nOn U.S. exchanges 9.75 billion shares changed hands compared with the 11.41 billion average for the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":618,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606114376,"gmtCreate":1638842490925,"gmtModify":1638842636823,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"thanks","listText":"thanks","text":"thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606114376","repostId":"1165217690","repostType":2,"repost":{"id":"1165217690","kind":"news","pubTimestamp":1638841605,"share":"https://www.laohu8.com/m/news/1165217690?lang=&edition=full","pubTime":"2021-12-07 09:46","market":"us","language":"en","title":"Vaccine Stocks: Why MRNA, BNTX, NVAX, PFE Stocks Are Stumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1165217690","media":"InvestorPlace","summary":"Good news for public health can sometimes mean bad news for vaccine stocks. Today reminded us exactl","content":"<p>Good news for public health can sometimes mean bad news for vaccine stocks. Today reminded us exactly why. After more than a week of ominous reports on the omicron virus and mounting speculation about its severity, yesterday brought some welcome news. Dr. Anthony Fauci, White House chief medical officer and a trusted expert on the virus, stated yesterday that some clear preliminary data was finally starting to emerge on the severity of the new variant and that so far, the results looked“encouraging.”</p>\n<p>What’s Happening With Vaccine Stocks</p>\n<p>Since news of the new variant first began dominating media airwaves, vaccine producers have been scrambling to be the first to address the new Covid-19 strain that threatened to undo the work that sent their stocks up earlier this year. Today has seen all the prominent names among vaccine stocks plunge across the board. While this isn’t strictly due to Dr. Fauci’s comments, it’s possible that the demand for new vaccine innovations and treatments may not be as great as we feared only a few days ago.</p>\n<p><b>BioNTech</b>&nbsp;(NASDAQ:<b><u>BNTX</u></b>) has suffered the worst declines of the day among vaccine stocks, with shares down almost 19% as of this writing. Next in line is&nbsp;<b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>), which has fallen more than 13%. Then,&nbsp;<b>Novavax’s</b>(NASDAQ:<b><u>NVAX</u></b>)declines come in just shy of 12%. Rounding out the pack is&nbsp;<b>Pfizer</b>(NYSE:<b><u>PFE</u></b>), which is in the red by just over 5% as trading winds to a close today.</p>\n<p>Why It Matters</p>\n<p>The clearest indication we should take from today’s events is that market mentality is shifting. This is evidenced by the performances we’ve seen not just from vaccine stocks but from other sectors that were differently affected by the spreading variant news. As&nbsp;<i>InvestorPlace’</i>s Shrey Dua reports,&nbsp;cruise ship stocks&nbsp;such as&nbsp;<b>Royal Caribbean</b>(NYSE:<b><u>RCL</u></b>) and&nbsp;<b>Carnival</b>(NYSE:<b><u>CCL</u></b>) are back in the green today after a troubling week of variant concerns. The same can be said for airline stocks, as names such as&nbsp;<b>Delta</b>&nbsp;(NYSE:<b><u>DAL</u></b>) and&nbsp;<b>Southwest</b>&nbsp;(NYSE:<b><u>LUV</u></b>) have gained some altitude today.</p>\n<p>Of course, it’s too soon to tell what the future will look like. The preliminary results upon which Dr. Fauci commented are exactly that — preliminary. Scientists and medical researchers still have plenty of research to do before they will be able outline a bigger picture. Dr. Fauci was careful to add that while there does not seem to be a “great degree of severity” to the spreading variant, it is still too early for any definitive conclusions to be reached. Omicron is still very much a variant of concern.</p>\n<p>What It Means</p>\n<p>Even if the variant does not end up posing as serious a threat to highly vaccinated countries as has been speculated, the need for vaccines isn’t going to go away. Fear of the variant has spiked&nbsp;demand&nbsp;for vaccinations in the U.S., and many countries are still struggling to get more of their populations partially or fully vaccinated. The industry landscape may not end up looking quite as bleak close to home as some of us have feared. However, that doesn’t mean that the demand for vaccines won’t be increasing throughout the months ahead.</p>\n<p>This news certainly doesn’t mean that a bearish play on vaccine stocks is advisable. Far from it, in fact. Novavax has an&nbsp;important catalyst&nbsp;rapidly approaching as the World Health Organization (WHO) considers granting it emergency use authorization. More than likely, vaccine stocks will be quick to rebound.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Stocks: Why MRNA, BNTX, NVAX, PFE Stocks Are Stumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Stocks: Why MRNA, BNTX, NVAX, PFE Stocks Are Stumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 09:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/vaccine-stocks-why-mrna-bntx-nvax-pfe-stocks-are-stumbling-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Good news for public health can sometimes mean bad news for vaccine stocks. Today reminded us exactly why. After more than a week of ominous reports on the omicron virus and mounting speculation about...</p>\n\n<a href=\"https://investorplace.com/2021/12/vaccine-stocks-why-mrna-bntx-nvax-pfe-stocks-are-stumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://investorplace.com/2021/12/vaccine-stocks-why-mrna-bntx-nvax-pfe-stocks-are-stumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165217690","content_text":"Good news for public health can sometimes mean bad news for vaccine stocks. Today reminded us exactly why. After more than a week of ominous reports on the omicron virus and mounting speculation about its severity, yesterday brought some welcome news. Dr. Anthony Fauci, White House chief medical officer and a trusted expert on the virus, stated yesterday that some clear preliminary data was finally starting to emerge on the severity of the new variant and that so far, the results looked“encouraging.”\nWhat’s Happening With Vaccine Stocks\nSince news of the new variant first began dominating media airwaves, vaccine producers have been scrambling to be the first to address the new Covid-19 strain that threatened to undo the work that sent their stocks up earlier this year. Today has seen all the prominent names among vaccine stocks plunge across the board. While this isn’t strictly due to Dr. Fauci’s comments, it’s possible that the demand for new vaccine innovations and treatments may not be as great as we feared only a few days ago.\nBioNTech (NASDAQ:BNTX) has suffered the worst declines of the day among vaccine stocks, with shares down almost 19% as of this writing. Next in line is Moderna(NASDAQ:MRNA), which has fallen more than 13%. Then, Novavax’s(NASDAQ:NVAX)declines come in just shy of 12%. Rounding out the pack is Pfizer(NYSE:PFE), which is in the red by just over 5% as trading winds to a close today.\nWhy It Matters\nThe clearest indication we should take from today’s events is that market mentality is shifting. This is evidenced by the performances we’ve seen not just from vaccine stocks but from other sectors that were differently affected by the spreading variant news. As InvestorPlace’s Shrey Dua reports, cruise ship stocks such as Royal Caribbean(NYSE:RCL) and Carnival(NYSE:CCL) are back in the green today after a troubling week of variant concerns. The same can be said for airline stocks, as names such as Delta (NYSE:DAL) and Southwest (NYSE:LUV) have gained some altitude today.\nOf course, it’s too soon to tell what the future will look like. The preliminary results upon which Dr. Fauci commented are exactly that — preliminary. Scientists and medical researchers still have plenty of research to do before they will be able outline a bigger picture. Dr. Fauci was careful to add that while there does not seem to be a “great degree of severity” to the spreading variant, it is still too early for any definitive conclusions to be reached. Omicron is still very much a variant of concern.\nWhat It Means\nEven if the variant does not end up posing as serious a threat to highly vaccinated countries as has been speculated, the need for vaccines isn’t going to go away. Fear of the variant has spiked demand for vaccinations in the U.S., and many countries are still struggling to get more of their populations partially or fully vaccinated. The industry landscape may not end up looking quite as bleak close to home as some of us have feared. However, that doesn’t mean that the demand for vaccines won’t be increasing throughout the months ahead.\nThis news certainly doesn’t mean that a bearish play on vaccine stocks is advisable. Far from it, in fact. Novavax has an important catalyst rapidly approaching as the World Health Organization (WHO) considers granting it emergency use authorization. More than likely, vaccine stocks will be quick to rebound.","news_type":1},"isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875895158,"gmtCreate":1637630310478,"gmtModify":1637630310478,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"go go go!!","listText":"go go go!!","text":"go go go!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875895158","repostId":"1144786882","repostType":2,"repost":{"id":"1144786882","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1637627337,"share":"https://www.laohu8.com/m/news/1144786882?lang=&edition=full","pubTime":"2021-11-23 08:28","market":"us","language":"en","title":"Can Apple Close Above The All-Time Highs This Week? Option Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=1144786882","media":"Benzinga","summary":"What Happened:Apple Inc is having a volatile day, initially up over 2.5% but having since lost all o","content":"<p><b>What Happened:Apple Inc</b>&nbsp;is having a volatile day, initially up over 2.5%&nbsp;but having since lost all of those gains over the last two hours of trading.</p>\n<p>Trading activity has been strong with over 104 million shares on the day versus the 10-day average of 78 million. The recent sell-off late in the session might be due to supply constraints out of Asia for the upcoming holiday shopping season.</p>\n<p>But what is fascinating is the heavy level of options activity in the stock today with&nbsp;<b>over 2.73 million contracts traded on the day</b>&nbsp;(see below).</p>\n<p><img src=\"https://static.tigerbbs.com/1a3445e396564690250472543787b2dd\" tg-width=\"1002\" tg-height=\"277\" width=\"100%\" height=\"auto\"></p>\n<p><b>Why It Matters:</b>Prior to Monday, Apple had approximately 4.1 million calls and 3.3 million puts for a total of 7.4 million options. Thus, today's 2.7+ million options represent&nbsp;<b>a massive 36% increase in options in one day.</b></p>\n<p>Any time a stock trades 36% of the total options in one day, it suggests option traders are highly active in the stock. And considering 73% of the options traded were calls, it suggests option traders have a strong bullish bias.</p>\n<p><b>What's Next:</b>&nbsp;About half of the option flows today were short-dated (expiring Friday) with the largest concentration of strikes between $160 and $170 (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/fdaae290e3e5538e2f6697fe9cbc40e9\" tg-width=\"1105\" tg-height=\"319\" width=\"100%\" height=\"auto\"></p>\n<p>The short-dated calls suggest option traders are targeting a range between $160 and $170 for the week. However, with the strong sell-off into the close, the stock could probe below the $160 strike.</p>\n<p>If Apple loses the $160 level, there is solid open interest down to the $155 strike, but falls off materially below that, so any sharp moves below here could represent a bigger selloff in the stock.</p>\n<p>Meanwhile, if the stock can break the all-time highs just above $165, there is potentially room for a move up towards the $175 level.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Apple Close Above The All-Time Highs This Week? Option Analysis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Apple Close Above The All-Time Highs This Week? Option Analysis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-11-23 08:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>What Happened:Apple Inc</b>&nbsp;is having a volatile day, initially up over 2.5%&nbsp;but having since lost all of those gains over the last two hours of trading.</p>\n<p>Trading activity has been strong with over 104 million shares on the day versus the 10-day average of 78 million. The recent sell-off late in the session might be due to supply constraints out of Asia for the upcoming holiday shopping season.</p>\n<p>But what is fascinating is the heavy level of options activity in the stock today with&nbsp;<b>over 2.73 million contracts traded on the day</b>&nbsp;(see below).</p>\n<p><img src=\"https://static.tigerbbs.com/1a3445e396564690250472543787b2dd\" tg-width=\"1002\" tg-height=\"277\" width=\"100%\" height=\"auto\"></p>\n<p><b>Why It Matters:</b>Prior to Monday, Apple had approximately 4.1 million calls and 3.3 million puts for a total of 7.4 million options. Thus, today's 2.7+ million options represent&nbsp;<b>a massive 36% increase in options in one day.</b></p>\n<p>Any time a stock trades 36% of the total options in one day, it suggests option traders are highly active in the stock. And considering 73% of the options traded were calls, it suggests option traders have a strong bullish bias.</p>\n<p><b>What's Next:</b>&nbsp;About half of the option flows today were short-dated (expiring Friday) with the largest concentration of strikes between $160 and $170 (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/fdaae290e3e5538e2f6697fe9cbc40e9\" tg-width=\"1105\" tg-height=\"319\" width=\"100%\" height=\"auto\"></p>\n<p>The short-dated calls suggest option traders are targeting a range between $160 and $170 for the week. However, with the strong sell-off into the close, the stock could probe below the $160 strike.</p>\n<p>If Apple loses the $160 level, there is solid open interest down to the $155 strike, but falls off materially below that, so any sharp moves below here could represent a bigger selloff in the stock.</p>\n<p>Meanwhile, if the stock can break the all-time highs just above $165, there is potentially room for a move up towards the $175 level.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144786882","content_text":"What Happened:Apple Inc is having a volatile day, initially up over 2.5% but having since lost all of those gains over the last two hours of trading.\nTrading activity has been strong with over 104 million shares on the day versus the 10-day average of 78 million. The recent sell-off late in the session might be due to supply constraints out of Asia for the upcoming holiday shopping season.\nBut what is fascinating is the heavy level of options activity in the stock today with over 2.73 million contracts traded on the day (see below).\n\nWhy It Matters:Prior to Monday, Apple had approximately 4.1 million calls and 3.3 million puts for a total of 7.4 million options. Thus, today's 2.7+ million options represent a massive 36% increase in options in one day.\nAny time a stock trades 36% of the total options in one day, it suggests option traders are highly active in the stock. And considering 73% of the options traded were calls, it suggests option traders have a strong bullish bias.\nWhat's Next: About half of the option flows today were short-dated (expiring Friday) with the largest concentration of strikes between $160 and $170 (image below).\n\nThe short-dated calls suggest option traders are targeting a range between $160 and $170 for the week. However, with the strong sell-off into the close, the stock could probe below the $160 strike.\nIf Apple loses the $160 level, there is solid open interest down to the $155 strike, but falls off materially below that, so any sharp moves below here could represent a bigger selloff in the stock.\nMeanwhile, if the stock can break the all-time highs just above $165, there is potentially room for a move up towards the $175 level.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1028,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872244053,"gmtCreate":1637542060223,"gmtModify":1637542060318,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"yeah","listText":"yeah","text":"yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/872244053","repostId":"1138408759","repostType":2,"repost":{"id":"1138408759","kind":"news","pubTimestamp":1637541844,"share":"https://www.laohu8.com/m/news/1138408759?lang=&edition=full","pubTime":"2021-11-22 08:44","market":"us","language":"en","title":"Why Elon Musk’s Tesla Stock Sales Are a Non-Event","url":"https://stock-news.laohu8.com/highlight/detail?id=1138408759","media":"InvestorPlace","summary":"TSLA stock is up more than 1,500% since February 2018","content":"<p>I moved to Halifax, Nova Scotia, from Toronto in February 2018. At the time,<b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>) was trading at $69 a share. If only I had bought a few hundred shares of TSLA stock back then. Today, I’d be lying on a beach somewhere.</p>\n<p>For those contemplating whether they should bet on Tesla now that it’s trading at over $1,100 a share, I don’t think the actual price matters too much in today’s world of fractional buying.</p>\n<p>What’s important is that Tesla still has plenty to prove, including delivering a pickup truck that can compete with&nbsp;<b>Rivian’s</b>(NASDAQ:<b><u>RIVN</u></b>) R1T and the rest of the electric startups sprouting up.</p>\n<p>Tesla CEO Elon Musk might be selling some of his stock, but I don’t think that means he’s giving up the fight. As long as he’s CEO and involved with the company, I don’t think you should worry yourself with the billionaire’s stock sales.Here’s why.</p>\n<p><b>Musk Polls Twitter Followers About Selling TSLA Stock</b></p>\n<p>On Nov. 6,Musk tweeted&nbsp;the following:“Much is made lately of unrealized gains being a means of tax avoidance, so I propose selling 10% of my Tesla stock. Do you support this?” He went on to add, “I will abide by the results of this poll, whichever way it goes.”</p>\n<p>Nearly 58% of the more than 3.5 millionpeople who responded said he should sell. And sell he has. Since Nov. 8, he has&nbsp;sold around 8.16 million shares for $8.8 billion, according to filings with the Securities and Exchange Commission. That puts him about halfway to the promised 10% stake.</p>\n<p>TSLA stock fell as much as 20%from itsNov. 5 closing price, the day before Musk’s cheeky tweet. As I write, shares are off around 7%.</p>\n<p>While this was the most significant correction in months, it pales in comparison to the drop in the first quarter of the year. TSLA stock plummeted 40% before bottoming out below $56o on March 8.If you purchased shares in early March, congratulations on your timely buy.</p>\n<p><b>Musk May Have Had No Choice But to Sell</b></p>\n<p>Now, if you’ve been following this story, you know there’s a bit more to it than Musk putting the fate of billions of dollars in his&nbsp;<b>Twitter</b>(NYSE:<b><u>TWTR</u></b>) followers’ hands.</p>\n<p>As&nbsp;<i>CNBC’s</i>&nbsp;Robert Frank reported on Nov. 7, Musk faced anestimated $15 billion tax bill. Frank&nbsp;does an&nbsp;excellent job explaining the billionaire’s predicament:</p>\n<blockquote>\n The options expire in August of next year. Yet in order to exercise them, Musk has to pay the income tax on the gain. Since the options are taxed as an employee benefit or compensation, they will be taxed at top ordinary-income levels, or 37% plus the 3.8% net investment tax. He will also have to pay the 13.3% top tax rate in California since the options were granted and mostly earned while he was a California tax resident.\n</blockquote>\n<blockquote>\n Combined, the state and federal tax rate will be 54.1%. So the total tax bill on his options, at the current price, would be $15 billion.\n</blockquote>\n<p>That’s a big number. But keep in mindMusk is the world’s wealthiest person with a&nbsp;net worth north of $300 billion, according to the Bloomberg Billionaires Index. So, that tax bill amounts toa mere 5% of his net worth.</p>\n<p>As of June 30,Musk owned about 244 million shares&nbsp;through his trust and stock options. Subtract the 8.16 million he recently sold and you get 235.84 million. Let’s assume he sells another 8.16 million to meet his 10% goal. That still leaves Musk with 227.68 million shares.</p>\n<p>As I’ve said many times, there’s only one reason insiders buy stock, but there are plenty of reasons insiders sell.The recent sales of TSLA stock by Musk are nothing more than financial and tax planning.</p>\n<p><b>The Bottom Line on TSLA Stock</b></p>\n<p>For its most recent quarter, Tesla reported&nbsp;record revenue&nbsp;of&nbsp;$13.76 billion and record net income of $1.62 billion. Through the first nine months of 2021, it generated$36.1 billion in revenueand $3.2 billion in net income.</p>\n<p>For the full year, analysts estimate the company will generate$51.1 billionin sales. That means TSLA stock is trading for 22.3 times this year’s projected sales. While that’s significantly higher than its price-to-sales ratio before shares started to take off in 2020, it’s not unreasonable for a company that looks ready to turn on the cash flow machine in 2022 and beyond.</p>\n<p>As CFO Zach Kirkhorn stated during the company’s Q3 earnings call, Tesla hit annualized production of&nbsp;more than 1 million vehicles. I’d be shocked if it didn’t&nbsp;hit 2 million&nbsp;by early 2023.</p>\n<p>If you’re thinking of buying TSLA stock, Musk’s stock sales are the last reason you should use for taking a pass. They’re a non-event.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Elon Musk’s Tesla Stock Sales Are a Non-Event</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Elon Musk’s Tesla Stock Sales Are a Non-Event\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-22 08:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/11/why-elon-musks-tsla-stock-sales-are-a-non-event/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I moved to Halifax, Nova Scotia, from Toronto in February 2018. At the time,Tesla(NASDAQ:TSLA) was trading at $69 a share. If only I had bought a few hundred shares of TSLA stock back then. Today, I’d...</p>\n\n<a href=\"https://investorplace.com/2021/11/why-elon-musks-tsla-stock-sales-are-a-non-event/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://investorplace.com/2021/11/why-elon-musks-tsla-stock-sales-are-a-non-event/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138408759","content_text":"I moved to Halifax, Nova Scotia, from Toronto in February 2018. At the time,Tesla(NASDAQ:TSLA) was trading at $69 a share. If only I had bought a few hundred shares of TSLA stock back then. Today, I’d be lying on a beach somewhere.\nFor those contemplating whether they should bet on Tesla now that it’s trading at over $1,100 a share, I don’t think the actual price matters too much in today’s world of fractional buying.\nWhat’s important is that Tesla still has plenty to prove, including delivering a pickup truck that can compete with Rivian’s(NASDAQ:RIVN) R1T and the rest of the electric startups sprouting up.\nTesla CEO Elon Musk might be selling some of his stock, but I don’t think that means he’s giving up the fight. As long as he’s CEO and involved with the company, I don’t think you should worry yourself with the billionaire’s stock sales.Here’s why.\nMusk Polls Twitter Followers About Selling TSLA Stock\nOn Nov. 6,Musk tweeted the following:“Much is made lately of unrealized gains being a means of tax avoidance, so I propose selling 10% of my Tesla stock. Do you support this?” He went on to add, “I will abide by the results of this poll, whichever way it goes.”\nNearly 58% of the more than 3.5 millionpeople who responded said he should sell. And sell he has. Since Nov. 8, he has sold around 8.16 million shares for $8.8 billion, according to filings with the Securities and Exchange Commission. That puts him about halfway to the promised 10% stake.\nTSLA stock fell as much as 20%from itsNov. 5 closing price, the day before Musk’s cheeky tweet. As I write, shares are off around 7%.\nWhile this was the most significant correction in months, it pales in comparison to the drop in the first quarter of the year. TSLA stock plummeted 40% before bottoming out below $56o on March 8.If you purchased shares in early March, congratulations on your timely buy.\nMusk May Have Had No Choice But to Sell\nNow, if you’ve been following this story, you know there’s a bit more to it than Musk putting the fate of billions of dollars in his Twitter(NYSE:TWTR) followers’ hands.\nAs CNBC’s Robert Frank reported on Nov. 7, Musk faced anestimated $15 billion tax bill. Frank does an excellent job explaining the billionaire’s predicament:\n\n The options expire in August of next year. Yet in order to exercise them, Musk has to pay the income tax on the gain. Since the options are taxed as an employee benefit or compensation, they will be taxed at top ordinary-income levels, or 37% plus the 3.8% net investment tax. He will also have to pay the 13.3% top tax rate in California since the options were granted and mostly earned while he was a California tax resident.\n\n\n Combined, the state and federal tax rate will be 54.1%. So the total tax bill on his options, at the current price, would be $15 billion.\n\nThat’s a big number. But keep in mindMusk is the world’s wealthiest person with a net worth north of $300 billion, according to the Bloomberg Billionaires Index. So, that tax bill amounts toa mere 5% of his net worth.\nAs of June 30,Musk owned about 244 million shares through his trust and stock options. Subtract the 8.16 million he recently sold and you get 235.84 million. Let’s assume he sells another 8.16 million to meet his 10% goal. That still leaves Musk with 227.68 million shares.\nAs I’ve said many times, there’s only one reason insiders buy stock, but there are plenty of reasons insiders sell.The recent sales of TSLA stock by Musk are nothing more than financial and tax planning.\nThe Bottom Line on TSLA Stock\nFor its most recent quarter, Tesla reported record revenue of $13.76 billion and record net income of $1.62 billion. Through the first nine months of 2021, it generated$36.1 billion in revenueand $3.2 billion in net income.\nFor the full year, analysts estimate the company will generate$51.1 billionin sales. That means TSLA stock is trading for 22.3 times this year’s projected sales. While that’s significantly higher than its price-to-sales ratio before shares started to take off in 2020, it’s not unreasonable for a company that looks ready to turn on the cash flow machine in 2022 and beyond.\nAs CFO Zach Kirkhorn stated during the company’s Q3 earnings call, Tesla hit annualized production of more than 1 million vehicles. I’d be shocked if it didn’t hit 2 million by early 2023.\nIf you’re thinking of buying TSLA stock, Musk’s stock sales are the last reason you should use for taking a pass. They’re a non-event.","news_type":1},"isVote":1,"tweetType":1,"viewCount":970,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872949266,"gmtCreate":1637405323787,"gmtModify":1637405325999,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"wa...&nbsp;","listText":"wa...&nbsp;","text":"wa...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872949266","repostId":"2184840345","repostType":2,"isVote":1,"tweetType":1,"viewCount":951,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876203545,"gmtCreate":1637313763461,"gmtModify":1637314167419,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"grats","listText":"grats","text":"grats","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876203545","repostId":"1143344231","repostType":2,"repost":{"id":"1143344231","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637312557,"share":"https://www.laohu8.com/m/news/1143344231?lang=&edition=full","pubTime":"2021-11-19 17:02","market":"us","language":"en","title":"Longeveron continued to climb over 50% in premarket trading as FDA approved its Lomecel-B for rare pediatric disease designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1143344231","media":"Tiger Newspress","summary":"Longeveron continued to climb over 50% in premarket trading as FDA approved its Lomecel-B for rare p","content":"<p>Longeveron&nbsp;continued&nbsp;to&nbsp;climb&nbsp;over&nbsp;50%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;as&nbsp;FDA&nbsp;approved its Lomecel-B for rare pediatric disease designation.<img src=\"https://static.tigerbbs.com/6b1cd0f83b93e7a6c6bdcdbba2cdbaa6\" tg-width=\"772\" tg-height=\"566\" width=\"100%\" height=\"auto\">The&nbsp;company&nbsp;announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants. Lomecel-B, an investigational allogeneic, bone marrow-derived medicinal signaling cell (MSC) product, is currently being evaluated in a Phase 2 trial.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron continued to climb over 50% in premarket trading as FDA approved its Lomecel-B for rare pediatric disease designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron continued to climb over 50% in premarket trading as FDA approved its Lomecel-B for rare pediatric disease designation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 17:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Longeveron&nbsp;continued&nbsp;to&nbsp;climb&nbsp;over&nbsp;50%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;as&nbsp;FDA&nbsp;approved its Lomecel-B for rare pediatric disease designation.<img src=\"https://static.tigerbbs.com/6b1cd0f83b93e7a6c6bdcdbba2cdbaa6\" tg-width=\"772\" tg-height=\"566\" width=\"100%\" height=\"auto\">The&nbsp;company&nbsp;announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants. Lomecel-B, an investigational allogeneic, bone marrow-derived medicinal signaling cell (MSC) product, is currently being evaluated in a Phase 2 trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143344231","content_text":"Longeveron continued to climb over 50% in premarket trading as FDA approved its Lomecel-B for rare pediatric disease designation.The company announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants. Lomecel-B, an investigational allogeneic, bone marrow-derived medicinal signaling cell (MSC) product, is currently being evaluated in a Phase 2 trial.","news_type":1},"isVote":1,"tweetType":1,"viewCount":435,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878301207,"gmtCreate":1637144617104,"gmtModify":1637144617104,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878301207","repostId":"1103932041","repostType":2,"repost":{"id":"1103932041","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637140078,"share":"https://www.laohu8.com/m/news/1103932041?lang=&edition=full","pubTime":"2021-11-17 17:07","market":"us","language":"en","title":"Tesla shares rose 1.4% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1103932041","media":"Tiger Newspress","summary":"Tesla shares rose 1.4% in premarket trading although Musk exercised more options, sold $973 million ","content":"<p>Tesla shares rose 1.4% in premarket trading&nbsp;although&nbsp;Musk exercised more options, sold $973 million for taxes.</p>\n<p><img src=\"https://static.tigerbbs.com/606f9df440d66783c7b5ea7dc15676df\" tg-width=\"850\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p>\n<p>Tesla Chief Executive Elon Musk sold another $973 million in stock to pay taxes after exercising options on Tuesday, filings showed after the electric vehicle maker's shares rebounded during regular trade.</p>\n<p>Musk acquired 2.1 million shares worth $2.2 billion at the Tuesday closing price and sold 934,091 for $973 million to pay taxes, the SEC filings showed.</p>\n<p>In a sector surge spearheaded by Rivian Automotive Inc&nbsp;and Lucid Group Inc, Tesla Inc&nbsp;rose 4.1% to close at $1,054.73, leaving its market capitalization down about $187 billion since before Muskbegan selling shareslast week.</p>\n<p>Rivian's stock jumped 15%, with the EV maker now up over 120% since its initial public offer last Wednesday.</p>\n<p>Rivian disclosed in a filing on Tuesday that its underwriters bought 22.95 million additional shares, boosting the total size of the IPO. Including those shares, Rivian's market capitalization rose to $153 billion, overtaking Volkswagen AG(VOWG_p.DE)by $14 billion and making the Irvine, California, company the world's third-most valuable carmaker.</p>\n<p>Lucid surged nearly 24% after it said reservations for its cars rose to 13,000 in the third quarter and that it is confident it will produce 20,000 of its upcoming Lucid Air sedans in 2022.</p>\n<p>The gain in Lucid's shares elevated its stock market value to $90 billion, overtaking Ford Motor Co(F.N)and leaving it $1 billion short of General Motors Co.</p>\n<p>Over the past week, Musk has sold about 8.2 million Tesla shares for around $8.8 billion. Those sales fulfill almost half of his pledge on Twitter to sell 10% of his stake in Tesla.</p>\n<p>Musk began selling shares last week after floating the idea in aTwitter poll.</p>\n<p>With electric-car makers increasingly in demand on Wall Street, Tesla's stock has surged more than 150% in the past 12 months.</p>\n<p>\"There's still plenty of buying interest because I still think ultimately investors are viewing this as a phase and viewing pullbacks as an opportunity,\" said Craig Erlam, senior market economist at OANDA.</p>\n<p>\"If you ask me where the share price is going to be six months from now, 12 months from now? I'd say it's more likely to be 20% higher than 20% lower.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla shares rose 1.4% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla shares rose 1.4% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-17 17:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tesla shares rose 1.4% in premarket trading&nbsp;although&nbsp;Musk exercised more options, sold $973 million for taxes.</p>\n<p><img src=\"https://static.tigerbbs.com/606f9df440d66783c7b5ea7dc15676df\" tg-width=\"850\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p>\n<p>Tesla Chief Executive Elon Musk sold another $973 million in stock to pay taxes after exercising options on Tuesday, filings showed after the electric vehicle maker's shares rebounded during regular trade.</p>\n<p>Musk acquired 2.1 million shares worth $2.2 billion at the Tuesday closing price and sold 934,091 for $973 million to pay taxes, the SEC filings showed.</p>\n<p>In a sector surge spearheaded by Rivian Automotive Inc&nbsp;and Lucid Group Inc, Tesla Inc&nbsp;rose 4.1% to close at $1,054.73, leaving its market capitalization down about $187 billion since before Muskbegan selling shareslast week.</p>\n<p>Rivian's stock jumped 15%, with the EV maker now up over 120% since its initial public offer last Wednesday.</p>\n<p>Rivian disclosed in a filing on Tuesday that its underwriters bought 22.95 million additional shares, boosting the total size of the IPO. Including those shares, Rivian's market capitalization rose to $153 billion, overtaking Volkswagen AG(VOWG_p.DE)by $14 billion and making the Irvine, California, company the world's third-most valuable carmaker.</p>\n<p>Lucid surged nearly 24% after it said reservations for its cars rose to 13,000 in the third quarter and that it is confident it will produce 20,000 of its upcoming Lucid Air sedans in 2022.</p>\n<p>The gain in Lucid's shares elevated its stock market value to $90 billion, overtaking Ford Motor Co(F.N)and leaving it $1 billion short of General Motors Co.</p>\n<p>Over the past week, Musk has sold about 8.2 million Tesla shares for around $8.8 billion. Those sales fulfill almost half of his pledge on Twitter to sell 10% of his stake in Tesla.</p>\n<p>Musk began selling shares last week after floating the idea in aTwitter poll.</p>\n<p>With electric-car makers increasingly in demand on Wall Street, Tesla's stock has surged more than 150% in the past 12 months.</p>\n<p>\"There's still plenty of buying interest because I still think ultimately investors are viewing this as a phase and viewing pullbacks as an opportunity,\" said Craig Erlam, senior market economist at OANDA.</p>\n<p>\"If you ask me where the share price is going to be six months from now, 12 months from now? I'd say it's more likely to be 20% higher than 20% lower.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103932041","content_text":"Tesla shares rose 1.4% in premarket trading although Musk exercised more options, sold $973 million for taxes.\n\nTesla Chief Executive Elon Musk sold another $973 million in stock to pay taxes after exercising options on Tuesday, filings showed after the electric vehicle maker's shares rebounded during regular trade.\nMusk acquired 2.1 million shares worth $2.2 billion at the Tuesday closing price and sold 934,091 for $973 million to pay taxes, the SEC filings showed.\nIn a sector surge spearheaded by Rivian Automotive Inc and Lucid Group Inc, Tesla Inc rose 4.1% to close at $1,054.73, leaving its market capitalization down about $187 billion since before Muskbegan selling shareslast week.\nRivian's stock jumped 15%, with the EV maker now up over 120% since its initial public offer last Wednesday.\nRivian disclosed in a filing on Tuesday that its underwriters bought 22.95 million additional shares, boosting the total size of the IPO. Including those shares, Rivian's market capitalization rose to $153 billion, overtaking Volkswagen AG(VOWG_p.DE)by $14 billion and making the Irvine, California, company the world's third-most valuable carmaker.\nLucid surged nearly 24% after it said reservations for its cars rose to 13,000 in the third quarter and that it is confident it will produce 20,000 of its upcoming Lucid Air sedans in 2022.\nThe gain in Lucid's shares elevated its stock market value to $90 billion, overtaking Ford Motor Co(F.N)and leaving it $1 billion short of General Motors Co.\nOver the past week, Musk has sold about 8.2 million Tesla shares for around $8.8 billion. Those sales fulfill almost half of his pledge on Twitter to sell 10% of his stake in Tesla.\nMusk began selling shares last week after floating the idea in aTwitter poll.\nWith electric-car makers increasingly in demand on Wall Street, Tesla's stock has surged more than 150% in the past 12 months.\n\"There's still plenty of buying interest because I still think ultimately investors are viewing this as a phase and viewing pullbacks as an opportunity,\" said Craig Erlam, senior market economist at OANDA.\n\"If you ask me where the share price is going to be six months from now, 12 months from now? I'd say it's more likely to be 20% higher than 20% lower.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":430,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878303481,"gmtCreate":1637144527827,"gmtModify":1637144527827,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"thanks!!","listText":"thanks!!","text":"thanks!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878303481","repostId":"2184511834","repostType":2,"isVote":1,"tweetType":1,"viewCount":110,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871634396,"gmtCreate":1637061979187,"gmtModify":1637061979250,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"oh no....","listText":"oh no....","text":"oh no....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871634396","repostId":"2183007300","repostType":2,"repost":{"id":"2183007300","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637061660,"share":"https://www.laohu8.com/m/news/2183007300?lang=&edition=full","pubTime":"2021-11-16 19:21","market":"us","language":"en","title":"Tesla stock falls 1.4% premarket, heads toward 4th-straight loss and 7th loss in 8 days","url":"https://stock-news.laohu8.com/highlight/detail?id=2183007300","media":"Dow Jones","summary":"MW Tesla stock falls 1.4% premarket, heads toward 4th-straight loss and 7th loss in 8 days\n\n\n \n\n\n$(E","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Tesla stock falls 1.4% premarket, heads toward 4th-straight loss and 7th loss in 8 days\n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  November 16, 2021 06:21 ET (11:21 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla stock falls 1.4% premarket, heads toward 4th-straight loss and 7th loss in 8 days</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla stock falls 1.4% premarket, heads toward 4th-straight loss and 7th loss in 8 days\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-16 19:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Tesla stock falls 1.4% premarket, heads toward 4th-straight loss and 7th loss in 8 days\n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  November 16, 2021 06:21 ET (11:21 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2183007300","content_text":"MW Tesla stock falls 1.4% premarket, heads toward 4th-straight loss and 7th loss in 8 days\n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  November 16, 2021 06:21 ET (11:21 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":534,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873709135,"gmtCreate":1636983414200,"gmtModify":1636983414200,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"yeah!!","listText":"yeah!!","text":"yeah!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873709135","repostId":"2183022451","repostType":2,"isVote":1,"tweetType":1,"viewCount":452,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873700129,"gmtCreate":1636983367696,"gmtModify":1636983367696,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"okies","listText":"okies","text":"okies","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873700129","repostId":"1113723753","repostType":2,"repost":{"id":"1113723753","kind":"news","pubTimestamp":1636982024,"share":"https://www.laohu8.com/m/news/1113723753?lang=&edition=full","pubTime":"2021-11-15 21:13","market":"us","language":"en","title":"4 Stocks Insiders Are Selling","url":"https://stock-news.laohu8.com/highlight/detail?id=1113723753","media":"Benzinga","summary":"When insiders sell shares, it indicates their concern in the company’s prospects or that they view t","content":"<p>When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.</p>\n<p>Below is a look at a few recent notable insider sales.</p>\n<p><b>Tesla</b></p>\n<ul>\n <li><b>The Trade:Tesla, Inc.</b>&nbsp;CEO Elon Musk&nbsp;<i>disposed a total of 1200000 shares</i>&nbsp;at an average price of $1,029.67. The insider received $1,235,607,328.52 as a result of the transaction.</li>\n <li><b>What’s Happening:</b>Tesla chief Elon Musk took to Twitter&nbsp;to mock Sen. Bernie Sanders (I-VT) after the progressive legislator made yet another social media pronouncement to increase taxes on the ultra-wealthy.</li>\n <li><b>What Tesla Does:</b>Founded in 2003 and based in Palo Alto, California, Tesla is a vertically integrated sustainable energy company that also aims to transition the world to electric mobility by making electric vehicles.</li>\n</ul>\n<p><b>Centene</b></p>\n<ul>\n <li><b>The Trade:Centene Corporation</b>&nbsp;Director John Roberts&nbsp;<i>sold a total of 44172 shares</i>&nbsp;at an average price of $75.04. The insider received $1,500,800.00 from selling those shares. The insider also acquired a total of 23100 shares.</li>\n <li><b>What’s Happening:</b>Centene, last month, reported Q3 adjusted EPS of $1.26, slightly beating the consensus estimate of $1.25.</li>\n <li><b>What Centene Does:</b>Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges.</li>\n</ul>\n<p><b>Pfizer</b></p>\n<ul>\n <li><b>The Trade:Pfizer Inc.</b>&nbsp;Group President John D Young&nbsp;<i>sold a total of 150000 shares</i>&nbsp;at an average price of $50.06. The insider received $7,508,732.08 as a result of the transaction.</li>\n <li><b>What’s Happening:</b>Biohaven Pharmaceutical Holding Company and Pfizer recently announced an agreement for rimegepant in markets outside the U.S.</li>\n <li><b>What Pfizer Does:</b>Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales.</li>\n</ul>\n<p><b>Box</b></p>\n<ul>\n <li><b>The Trade:Box, Inc.</b>&nbsp;Chief Financial Officer Dylan Smith&nbsp;<i>sold a total of 15000 shares</i>&nbsp;at an average price of $26.45. The insider received $396,750.00 from selling those shares.</li>\n <li><b>What’s Happening:</b>Box recently announced that the U.S. General Services Administration (GSA) has selected Box Sign technology for its native e-signature capability.</li>\n <li><b>What Box Does:</b>Box was founded in 2005 as a natively built cloud file sync and sharing provider for enterprises. Box is headquartered in Redwood City, California.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Stocks Insiders Are Selling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Stocks Insiders Are Selling\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/11/24089327/4-stocks-insiders-are-selling><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. ...</p>\n\n<a href=\"https://www.benzinga.com/news/21/11/24089327/4-stocks-insiders-are-selling\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BOX":"Box Inc","TSLA":"特斯拉","CNC":"康西哥"},"source_url":"https://www.benzinga.com/news/21/11/24089327/4-stocks-insiders-are-selling","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113723753","content_text":"When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.\nBelow is a look at a few recent notable insider sales.\nTesla\n\nThe Trade:Tesla, Inc. CEO Elon Musk disposed a total of 1200000 shares at an average price of $1,029.67. The insider received $1,235,607,328.52 as a result of the transaction.\nWhat’s Happening:Tesla chief Elon Musk took to Twitter to mock Sen. Bernie Sanders (I-VT) after the progressive legislator made yet another social media pronouncement to increase taxes on the ultra-wealthy.\nWhat Tesla Does:Founded in 2003 and based in Palo Alto, California, Tesla is a vertically integrated sustainable energy company that also aims to transition the world to electric mobility by making electric vehicles.\n\nCentene\n\nThe Trade:Centene Corporation Director John Roberts sold a total of 44172 shares at an average price of $75.04. The insider received $1,500,800.00 from selling those shares. The insider also acquired a total of 23100 shares.\nWhat’s Happening:Centene, last month, reported Q3 adjusted EPS of $1.26, slightly beating the consensus estimate of $1.25.\nWhat Centene Does:Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges.\n\nPfizer\n\nThe Trade:Pfizer Inc. Group President John D Young sold a total of 150000 shares at an average price of $50.06. The insider received $7,508,732.08 as a result of the transaction.\nWhat’s Happening:Biohaven Pharmaceutical Holding Company and Pfizer recently announced an agreement for rimegepant in markets outside the U.S.\nWhat Pfizer Does:Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales.\n\nBox\n\nThe Trade:Box, Inc. Chief Financial Officer Dylan Smith sold a total of 15000 shares at an average price of $26.45. The insider received $396,750.00 from selling those shares.\nWhat’s Happening:Box recently announced that the U.S. General Services Administration (GSA) has selected Box Sign technology for its native e-signature capability.\nWhat Box Does:Box was founded in 2005 as a natively built cloud file sync and sharing provider for enterprises. Box is headquartered in Redwood City, California.","news_type":1},"isVote":1,"tweetType":1,"viewCount":213,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873541663,"gmtCreate":1636967682367,"gmtModify":1636967682367,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"yeah","listText":"yeah","text":"yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873541663","repostId":"2183286630","repostType":2,"isVote":1,"tweetType":1,"viewCount":279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873541909,"gmtCreate":1636967645350,"gmtModify":1636967645350,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"oh no","listText":"oh no","text":"oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/873541909","repostId":"1172705595","repostType":2,"isVote":1,"tweetType":1,"viewCount":414,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879762019,"gmtCreate":1636774574138,"gmtModify":1636774574138,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098771492575270","idStr":"4098771492575270"},"themes":[],"htmlText":"Like!!","listText":"Like!!","text":"Like!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879762019","repostId":"1102251183","repostType":2,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":300,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":691927406,"gmtCreate":1640129487937,"gmtModify":1640138964321,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"Novavax (NVAX) is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck.\"We will be filing within the next few days in the U.S.,\" Erck told Yahoo Finance Live on Tuesday.The company has made significant progress on its path to its first commercial product, the two-dose COVID-19 vaccine, marking three major milestones in the past week.Novavax has now received four emergency use approvals, including a listing from the World Health Organization, making it the ninth vaccine authorized by the agency, as well as conditional marketing in the European Union. In addition, the company announced administering its first dose in Indonesia Tuesday, where it recently received emergency use authorizat","listText":"Novavax (NVAX) is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck.\"We will be filing within the next few days in the U.S.,\" Erck told Yahoo Finance Live on Tuesday.The company has made significant progress on its path to its first commercial product, the two-dose COVID-19 vaccine, marking three major milestones in the past week.Novavax has now received four emergency use approvals, including a listing from the World Health Organization, making it the ninth vaccine authorized by the agency, as well as conditional marketing in the European Union. In addition, the company announced administering its first dose in Indonesia Tuesday, where it recently received emergency use authorizat","text":"Novavax (NVAX) is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck.\"We will be filing within the next few days in the U.S.,\" Erck told Yahoo Finance Live on Tuesday.The company has made significant progress on its path to its first commercial product, the two-dose COVID-19 vaccine, marking three major milestones in the past week.Novavax has now received four emergency use approvals, including a listing from the World Health Organization, making it the ninth vaccine authorized by the agency, as well as conditional marketing in the European Union. In addition, the company announced administering its first dose in Indonesia Tuesday, where it recently received emergency use authorizat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/691927406","isVote":1,"tweetType":1,"viewCount":2426,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000408","authorId":"9000000000000408","name":"RodBeard","avatar":"https://static.tigerbbs.com/af002b44e35ebf40cafbbaf194de9c06","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000408","authorIdStr":"9000000000000408"},"content":"Novavax is a great company. However, with the gradual weakening of the epidemic, we should not buy or hold the shares of this company now.","text":"Novavax is a great company. However, with the gradual weakening of the epidemic, we should not buy or hold the shares of this company now.","html":"Novavax is a great company. However, with the gradual weakening of the epidemic, we should not buy or hold the shares of this company now."}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691953728,"gmtCreate":1640129700173,"gmtModify":1640138818666,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"title":"WHO recommends 4th dose of vaccination","htmlText":"Dec 21 (Reuters) - Novavax said on Tuesday the World Health Organization's (WHO) panel of experts had recommended a third dose of its vaccine, NVX-CoV2373, for immunocompromised persons.The WHO's Strategic Advisory Group of Experts on Immunization, known as SAGE, issued a series of recommendations, including the use of the vaccine in persons with comorbidities, breastfeeding women, and those living with HIV.After reviewing Novavax data the independent experts said the vaccine could be used in pregnant women if the benefits of vaccination to the pregnant woman outweigh the potential risks.On Friday, the WHO issued an emergency use listing to Novavax's vaccine made by the Serum Institute of India, the world's biggest vaccine maker, paving the way for its use in low- and middle-income countri","listText":"Dec 21 (Reuters) - Novavax said on Tuesday the World Health Organization's (WHO) panel of experts had recommended a third dose of its vaccine, NVX-CoV2373, for immunocompromised persons.The WHO's Strategic Advisory Group of Experts on Immunization, known as SAGE, issued a series of recommendations, including the use of the vaccine in persons with comorbidities, breastfeeding women, and those living with HIV.After reviewing Novavax data the independent experts said the vaccine could be used in pregnant women if the benefits of vaccination to the pregnant woman outweigh the potential risks.On Friday, the WHO issued an emergency use listing to Novavax's vaccine made by the Serum Institute of India, the world's biggest vaccine maker, paving the way for its use in low- and middle-income countri","text":"Dec 21 (Reuters) - Novavax said on Tuesday the World Health Organization's (WHO) panel of experts had recommended a third dose of its vaccine, NVX-CoV2373, for immunocompromised persons.The WHO's Strategic Advisory Group of Experts on Immunization, known as SAGE, issued a series of recommendations, including the use of the vaccine in persons with comorbidities, breastfeeding women, and those living with HIV.After reviewing Novavax data the independent experts said the vaccine could be used in pregnant women if the benefits of vaccination to the pregnant woman outweigh the potential risks.On Friday, the WHO issued an emergency use listing to Novavax's vaccine made by the Serum Institute of India, the world's biggest vaccine maker, paving the way for its use in low- and middle-income countri","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":5,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/691953728","isVote":1,"tweetType":1,"viewCount":2003,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000408","authorId":"9000000000000408","name":"RodBeard","avatar":"https://static.tigerbbs.com/af002b44e35ebf40cafbbaf194de9c06","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000408","authorIdStr":"9000000000000408"},"content":"This is important for the global economic recovery in 2022.","text":"This is important for the global economic recovery in 2022.","html":"This is important for the global economic recovery in 2022."}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691950560,"gmtCreate":1640129527524,"gmtModify":1640138892313,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"Novavax (NVAX) is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck.\"We will be filing within the next few days in the U.S.,\" Erck told Yahoo Finance Live on Tuesday.The company has made significant progress on its path to its first commercial product, the two-dose COVID-19 vaccine, marking three major milestones in the past week.Novavax has now received four emergency use approvals, including a listing from the World Health Organization, making it the ninth vaccine authorized by the agency, as well as conditional marketing in the European Union. In addition, the company announced administering its first dose in Indonesia Tuesday, where it recently received emergency use authorizat","listText":"Novavax (NVAX) is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck.\"We will be filing within the next few days in the U.S.,\" Erck told Yahoo Finance Live on Tuesday.The company has made significant progress on its path to its first commercial product, the two-dose COVID-19 vaccine, marking three major milestones in the past week.Novavax has now received four emergency use approvals, including a listing from the World Health Organization, making it the ninth vaccine authorized by the agency, as well as conditional marketing in the European Union. In addition, the company announced administering its first dose in Indonesia Tuesday, where it recently received emergency use authorizat","text":"Novavax (NVAX) is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck.\"We will be filing within the next few days in the U.S.,\" Erck told Yahoo Finance Live on Tuesday.The company has made significant progress on its path to its first commercial product, the two-dose COVID-19 vaccine, marking three major milestones in the past week.Novavax has now received four emergency use approvals, including a listing from the World Health Organization, making it the ninth vaccine authorized by the agency, as well as conditional marketing in the European Union. In addition, the company announced administering its first dose in Indonesia Tuesday, where it recently received emergency use authorizat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/691950560","isVote":1,"tweetType":1,"viewCount":2821,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000408","authorId":"9000000000000408","name":"RodBeard","avatar":"https://static.tigerbbs.com/af002b44e35ebf40cafbbaf194de9c06","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000408","authorIdStr":"9000000000000408"},"content":"Novavax is a great company. However, with the gradual weakening of the epidemic, we should not buy or hold the shares of this company now.","text":"Novavax is a great company. However, with the gradual weakening of the epidemic, we should not buy or hold the shares of this company now.","html":"Novavax is a great company. However, with the gradual weakening of the epidemic, we should not buy or hold the shares of this company now."}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873541909,"gmtCreate":1636967645350,"gmtModify":1636967645350,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"oh no","listText":"oh no","text":"oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/873541909","repostId":"1172705595","repostType":2,"repost":{"id":"1172705595","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636967300,"share":"https://www.laohu8.com/m/news/1172705595?lang=&edition=full","pubTime":"2021-11-15 17:08","market":"us","language":"en","title":"Tesla slid over 2% in premarket trading as Musk sold $6.9 billion in stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1172705595","media":"Tiger Newspress","summary":"Tesla slid over 2% in premarket trading as Musk sold $6.9 billion in stocks.According to the SEC doc","content":"<p>Tesla slid over 2% in premarket trading as&nbsp;Musk&nbsp;sold&nbsp;$6.9 billion in stocks.<img src=\"https://static.tigerbbs.com/5a221e68493f92069795f4cb1ba56aa5\" tg-width=\"765\" tg-height=\"566\" width=\"100%\" height=\"auto\">According to the SEC documents,Tesla&nbsp;CEO Musk sold 1.2 million Tesla Motors shares held by his trust fund on November 12, worth more than $1.2 billion.</p>\n<p>According to media statistics, up to now, Musk has sold about 6.36 million Tesla Motors shares in the week since November 8, with a total value of nearly 6.9 billion US dollars (equivalent to about 44 billion yuan), and Tesla Motors's share price has also dropped by more than 15% in three days.</p>\n<p>Just before selling Tesla Motors shares, on November 6, Musk was in&nbsp;Twitter&nbsp;To ask 62.7 million fans whether they should sell 10% of Tesla Motors shares (worth $21 billion). He also said that regardless of the outcome, he would \"abide by the voting results\". The final vote showed that about 58% of the participants supported the sale.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla slid over 2% in premarket trading as Musk sold $6.9 billion in stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla slid over 2% in premarket trading as Musk sold $6.9 billion in stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-15 17:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tesla slid over 2% in premarket trading as&nbsp;Musk&nbsp;sold&nbsp;$6.9 billion in stocks.<img src=\"https://static.tigerbbs.com/5a221e68493f92069795f4cb1ba56aa5\" tg-width=\"765\" tg-height=\"566\" width=\"100%\" height=\"auto\">According to the SEC documents,Tesla&nbsp;CEO Musk sold 1.2 million Tesla Motors shares held by his trust fund on November 12, worth more than $1.2 billion.</p>\n<p>According to media statistics, up to now, Musk has sold about 6.36 million Tesla Motors shares in the week since November 8, with a total value of nearly 6.9 billion US dollars (equivalent to about 44 billion yuan), and Tesla Motors's share price has also dropped by more than 15% in three days.</p>\n<p>Just before selling Tesla Motors shares, on November 6, Musk was in&nbsp;Twitter&nbsp;To ask 62.7 million fans whether they should sell 10% of Tesla Motors shares (worth $21 billion). He also said that regardless of the outcome, he would \"abide by the voting results\". The final vote showed that about 58% of the participants supported the sale.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172705595","content_text":"Tesla slid over 2% in premarket trading as Musk sold $6.9 billion in stocks.According to the SEC documents,Tesla CEO Musk sold 1.2 million Tesla Motors shares held by his trust fund on November 12, worth more than $1.2 billion.\nAccording to media statistics, up to now, Musk has sold about 6.36 million Tesla Motors shares in the week since November 8, with a total value of nearly 6.9 billion US dollars (equivalent to about 44 billion yuan), and Tesla Motors's share price has also dropped by more than 15% in three days.\nJust before selling Tesla Motors shares, on November 6, Musk was in Twitter To ask 62.7 million fans whether they should sell 10% of Tesla Motors shares (worth $21 billion). He also said that regardless of the outcome, he would \"abide by the voting results\". The final vote showed that about 58% of the participants supported the sale.","news_type":1},"isVote":1,"tweetType":1,"viewCount":414,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872244053,"gmtCreate":1637542060223,"gmtModify":1637542060318,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"yeah","listText":"yeah","text":"yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/872244053","repostId":"1138408759","repostType":2,"repost":{"id":"1138408759","kind":"news","pubTimestamp":1637541844,"share":"https://www.laohu8.com/m/news/1138408759?lang=&edition=full","pubTime":"2021-11-22 08:44","market":"us","language":"en","title":"Why Elon Musk’s Tesla Stock Sales Are a Non-Event","url":"https://stock-news.laohu8.com/highlight/detail?id=1138408759","media":"InvestorPlace","summary":"TSLA stock is up more than 1,500% since February 2018","content":"<p>I moved to Halifax, Nova Scotia, from Toronto in February 2018. At the time,<b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>) was trading at $69 a share. If only I had bought a few hundred shares of TSLA stock back then. Today, I’d be lying on a beach somewhere.</p>\n<p>For those contemplating whether they should bet on Tesla now that it’s trading at over $1,100 a share, I don’t think the actual price matters too much in today’s world of fractional buying.</p>\n<p>What’s important is that Tesla still has plenty to prove, including delivering a pickup truck that can compete with&nbsp;<b>Rivian’s</b>(NASDAQ:<b><u>RIVN</u></b>) R1T and the rest of the electric startups sprouting up.</p>\n<p>Tesla CEO Elon Musk might be selling some of his stock, but I don’t think that means he’s giving up the fight. As long as he’s CEO and involved with the company, I don’t think you should worry yourself with the billionaire’s stock sales.Here’s why.</p>\n<p><b>Musk Polls Twitter Followers About Selling TSLA Stock</b></p>\n<p>On Nov. 6,Musk tweeted&nbsp;the following:“Much is made lately of unrealized gains being a means of tax avoidance, so I propose selling 10% of my Tesla stock. Do you support this?” He went on to add, “I will abide by the results of this poll, whichever way it goes.”</p>\n<p>Nearly 58% of the more than 3.5 millionpeople who responded said he should sell. And sell he has. Since Nov. 8, he has&nbsp;sold around 8.16 million shares for $8.8 billion, according to filings with the Securities and Exchange Commission. That puts him about halfway to the promised 10% stake.</p>\n<p>TSLA stock fell as much as 20%from itsNov. 5 closing price, the day before Musk’s cheeky tweet. As I write, shares are off around 7%.</p>\n<p>While this was the most significant correction in months, it pales in comparison to the drop in the first quarter of the year. TSLA stock plummeted 40% before bottoming out below $56o on March 8.If you purchased shares in early March, congratulations on your timely buy.</p>\n<p><b>Musk May Have Had No Choice But to Sell</b></p>\n<p>Now, if you’ve been following this story, you know there’s a bit more to it than Musk putting the fate of billions of dollars in his&nbsp;<b>Twitter</b>(NYSE:<b><u>TWTR</u></b>) followers’ hands.</p>\n<p>As&nbsp;<i>CNBC’s</i>&nbsp;Robert Frank reported on Nov. 7, Musk faced anestimated $15 billion tax bill. Frank&nbsp;does an&nbsp;excellent job explaining the billionaire’s predicament:</p>\n<blockquote>\n The options expire in August of next year. Yet in order to exercise them, Musk has to pay the income tax on the gain. Since the options are taxed as an employee benefit or compensation, they will be taxed at top ordinary-income levels, or 37% plus the 3.8% net investment tax. He will also have to pay the 13.3% top tax rate in California since the options were granted and mostly earned while he was a California tax resident.\n</blockquote>\n<blockquote>\n Combined, the state and federal tax rate will be 54.1%. So the total tax bill on his options, at the current price, would be $15 billion.\n</blockquote>\n<p>That’s a big number. But keep in mindMusk is the world’s wealthiest person with a&nbsp;net worth north of $300 billion, according to the Bloomberg Billionaires Index. So, that tax bill amounts toa mere 5% of his net worth.</p>\n<p>As of June 30,Musk owned about 244 million shares&nbsp;through his trust and stock options. Subtract the 8.16 million he recently sold and you get 235.84 million. Let’s assume he sells another 8.16 million to meet his 10% goal. That still leaves Musk with 227.68 million shares.</p>\n<p>As I’ve said many times, there’s only one reason insiders buy stock, but there are plenty of reasons insiders sell.The recent sales of TSLA stock by Musk are nothing more than financial and tax planning.</p>\n<p><b>The Bottom Line on TSLA Stock</b></p>\n<p>For its most recent quarter, Tesla reported&nbsp;record revenue&nbsp;of&nbsp;$13.76 billion and record net income of $1.62 billion. Through the first nine months of 2021, it generated$36.1 billion in revenueand $3.2 billion in net income.</p>\n<p>For the full year, analysts estimate the company will generate$51.1 billionin sales. That means TSLA stock is trading for 22.3 times this year’s projected sales. While that’s significantly higher than its price-to-sales ratio before shares started to take off in 2020, it’s not unreasonable for a company that looks ready to turn on the cash flow machine in 2022 and beyond.</p>\n<p>As CFO Zach Kirkhorn stated during the company’s Q3 earnings call, Tesla hit annualized production of&nbsp;more than 1 million vehicles. I’d be shocked if it didn’t&nbsp;hit 2 million&nbsp;by early 2023.</p>\n<p>If you’re thinking of buying TSLA stock, Musk’s stock sales are the last reason you should use for taking a pass. They’re a non-event.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Elon Musk’s Tesla Stock Sales Are a Non-Event</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Elon Musk’s Tesla Stock Sales Are a Non-Event\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-22 08:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/11/why-elon-musks-tsla-stock-sales-are-a-non-event/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I moved to Halifax, Nova Scotia, from Toronto in February 2018. At the time,Tesla(NASDAQ:TSLA) was trading at $69 a share. If only I had bought a few hundred shares of TSLA stock back then. Today, I’d...</p>\n\n<a href=\"https://investorplace.com/2021/11/why-elon-musks-tsla-stock-sales-are-a-non-event/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://investorplace.com/2021/11/why-elon-musks-tsla-stock-sales-are-a-non-event/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138408759","content_text":"I moved to Halifax, Nova Scotia, from Toronto in February 2018. At the time,Tesla(NASDAQ:TSLA) was trading at $69 a share. If only I had bought a few hundred shares of TSLA stock back then. Today, I’d be lying on a beach somewhere.\nFor those contemplating whether they should bet on Tesla now that it’s trading at over $1,100 a share, I don’t think the actual price matters too much in today’s world of fractional buying.\nWhat’s important is that Tesla still has plenty to prove, including delivering a pickup truck that can compete with Rivian’s(NASDAQ:RIVN) R1T and the rest of the electric startups sprouting up.\nTesla CEO Elon Musk might be selling some of his stock, but I don’t think that means he’s giving up the fight. As long as he’s CEO and involved with the company, I don’t think you should worry yourself with the billionaire’s stock sales.Here’s why.\nMusk Polls Twitter Followers About Selling TSLA Stock\nOn Nov. 6,Musk tweeted the following:“Much is made lately of unrealized gains being a means of tax avoidance, so I propose selling 10% of my Tesla stock. Do you support this?” He went on to add, “I will abide by the results of this poll, whichever way it goes.”\nNearly 58% of the more than 3.5 millionpeople who responded said he should sell. And sell he has. Since Nov. 8, he has sold around 8.16 million shares for $8.8 billion, according to filings with the Securities and Exchange Commission. That puts him about halfway to the promised 10% stake.\nTSLA stock fell as much as 20%from itsNov. 5 closing price, the day before Musk’s cheeky tweet. As I write, shares are off around 7%.\nWhile this was the most significant correction in months, it pales in comparison to the drop in the first quarter of the year. TSLA stock plummeted 40% before bottoming out below $56o on March 8.If you purchased shares in early March, congratulations on your timely buy.\nMusk May Have Had No Choice But to Sell\nNow, if you’ve been following this story, you know there’s a bit more to it than Musk putting the fate of billions of dollars in his Twitter(NYSE:TWTR) followers’ hands.\nAs CNBC’s Robert Frank reported on Nov. 7, Musk faced anestimated $15 billion tax bill. Frank does an excellent job explaining the billionaire’s predicament:\n\n The options expire in August of next year. Yet in order to exercise them, Musk has to pay the income tax on the gain. Since the options are taxed as an employee benefit or compensation, they will be taxed at top ordinary-income levels, or 37% plus the 3.8% net investment tax. He will also have to pay the 13.3% top tax rate in California since the options were granted and mostly earned while he was a California tax resident.\n\n\n Combined, the state and federal tax rate will be 54.1%. So the total tax bill on his options, at the current price, would be $15 billion.\n\nThat’s a big number. But keep in mindMusk is the world’s wealthiest person with a net worth north of $300 billion, according to the Bloomberg Billionaires Index. So, that tax bill amounts toa mere 5% of his net worth.\nAs of June 30,Musk owned about 244 million shares through his trust and stock options. Subtract the 8.16 million he recently sold and you get 235.84 million. Let’s assume he sells another 8.16 million to meet his 10% goal. That still leaves Musk with 227.68 million shares.\nAs I’ve said many times, there’s only one reason insiders buy stock, but there are plenty of reasons insiders sell.The recent sales of TSLA stock by Musk are nothing more than financial and tax planning.\nThe Bottom Line on TSLA Stock\nFor its most recent quarter, Tesla reported record revenue of $13.76 billion and record net income of $1.62 billion. Through the first nine months of 2021, it generated$36.1 billion in revenueand $3.2 billion in net income.\nFor the full year, analysts estimate the company will generate$51.1 billionin sales. That means TSLA stock is trading for 22.3 times this year’s projected sales. While that’s significantly higher than its price-to-sales ratio before shares started to take off in 2020, it’s not unreasonable for a company that looks ready to turn on the cash flow machine in 2022 and beyond.\nAs CFO Zach Kirkhorn stated during the company’s Q3 earnings call, Tesla hit annualized production of more than 1 million vehicles. I’d be shocked if it didn’t hit 2 million by early 2023.\nIf you’re thinking of buying TSLA stock, Musk’s stock sales are the last reason you should use for taking a pass. They’re a non-event.","news_type":1},"isVote":1,"tweetType":1,"viewCount":970,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873700129,"gmtCreate":1636983367696,"gmtModify":1636983367696,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"okies","listText":"okies","text":"okies","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873700129","repostId":"1113723753","repostType":2,"repost":{"id":"1113723753","kind":"news","pubTimestamp":1636982024,"share":"https://www.laohu8.com/m/news/1113723753?lang=&edition=full","pubTime":"2021-11-15 21:13","market":"us","language":"en","title":"4 Stocks Insiders Are Selling","url":"https://stock-news.laohu8.com/highlight/detail?id=1113723753","media":"Benzinga","summary":"When insiders sell shares, it indicates their concern in the company’s prospects or that they view t","content":"<p>When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.</p>\n<p>Below is a look at a few recent notable insider sales.</p>\n<p><b>Tesla</b></p>\n<ul>\n <li><b>The Trade:Tesla, Inc.</b>&nbsp;CEO Elon Musk&nbsp;<i>disposed a total of 1200000 shares</i>&nbsp;at an average price of $1,029.67. The insider received $1,235,607,328.52 as a result of the transaction.</li>\n <li><b>What’s Happening:</b>Tesla chief Elon Musk took to Twitter&nbsp;to mock Sen. Bernie Sanders (I-VT) after the progressive legislator made yet another social media pronouncement to increase taxes on the ultra-wealthy.</li>\n <li><b>What Tesla Does:</b>Founded in 2003 and based in Palo Alto, California, Tesla is a vertically integrated sustainable energy company that also aims to transition the world to electric mobility by making electric vehicles.</li>\n</ul>\n<p><b>Centene</b></p>\n<ul>\n <li><b>The Trade:Centene Corporation</b>&nbsp;Director John Roberts&nbsp;<i>sold a total of 44172 shares</i>&nbsp;at an average price of $75.04. The insider received $1,500,800.00 from selling those shares. The insider also acquired a total of 23100 shares.</li>\n <li><b>What’s Happening:</b>Centene, last month, reported Q3 adjusted EPS of $1.26, slightly beating the consensus estimate of $1.25.</li>\n <li><b>What Centene Does:</b>Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges.</li>\n</ul>\n<p><b>Pfizer</b></p>\n<ul>\n <li><b>The Trade:Pfizer Inc.</b>&nbsp;Group President John D Young&nbsp;<i>sold a total of 150000 shares</i>&nbsp;at an average price of $50.06. The insider received $7,508,732.08 as a result of the transaction.</li>\n <li><b>What’s Happening:</b>Biohaven Pharmaceutical Holding Company and Pfizer recently announced an agreement for rimegepant in markets outside the U.S.</li>\n <li><b>What Pfizer Does:</b>Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales.</li>\n</ul>\n<p><b>Box</b></p>\n<ul>\n <li><b>The Trade:Box, Inc.</b>&nbsp;Chief Financial Officer Dylan Smith&nbsp;<i>sold a total of 15000 shares</i>&nbsp;at an average price of $26.45. The insider received $396,750.00 from selling those shares.</li>\n <li><b>What’s Happening:</b>Box recently announced that the U.S. General Services Administration (GSA) has selected Box Sign technology for its native e-signature capability.</li>\n <li><b>What Box Does:</b>Box was founded in 2005 as a natively built cloud file sync and sharing provider for enterprises. Box is headquartered in Redwood City, California.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Stocks Insiders Are Selling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Stocks Insiders Are Selling\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/11/24089327/4-stocks-insiders-are-selling><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. ...</p>\n\n<a href=\"https://www.benzinga.com/news/21/11/24089327/4-stocks-insiders-are-selling\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BOX":"Box Inc","TSLA":"特斯拉","CNC":"康西哥"},"source_url":"https://www.benzinga.com/news/21/11/24089327/4-stocks-insiders-are-selling","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113723753","content_text":"When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.\nBelow is a look at a few recent notable insider sales.\nTesla\n\nThe Trade:Tesla, Inc. CEO Elon Musk disposed a total of 1200000 shares at an average price of $1,029.67. The insider received $1,235,607,328.52 as a result of the transaction.\nWhat’s Happening:Tesla chief Elon Musk took to Twitter to mock Sen. Bernie Sanders (I-VT) after the progressive legislator made yet another social media pronouncement to increase taxes on the ultra-wealthy.\nWhat Tesla Does:Founded in 2003 and based in Palo Alto, California, Tesla is a vertically integrated sustainable energy company that also aims to transition the world to electric mobility by making electric vehicles.\n\nCentene\n\nThe Trade:Centene Corporation Director John Roberts sold a total of 44172 shares at an average price of $75.04. The insider received $1,500,800.00 from selling those shares. The insider also acquired a total of 23100 shares.\nWhat’s Happening:Centene, last month, reported Q3 adjusted EPS of $1.26, slightly beating the consensus estimate of $1.25.\nWhat Centene Does:Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges.\n\nPfizer\n\nThe Trade:Pfizer Inc. Group President John D Young sold a total of 150000 shares at an average price of $50.06. The insider received $7,508,732.08 as a result of the transaction.\nWhat’s Happening:Biohaven Pharmaceutical Holding Company and Pfizer recently announced an agreement for rimegepant in markets outside the U.S.\nWhat Pfizer Does:Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales.\n\nBox\n\nThe Trade:Box, Inc. Chief Financial Officer Dylan Smith sold a total of 15000 shares at an average price of $26.45. The insider received $396,750.00 from selling those shares.\nWhat’s Happening:Box recently announced that the U.S. General Services Administration (GSA) has selected Box Sign technology for its native e-signature capability.\nWhat Box Does:Box was founded in 2005 as a natively built cloud file sync and sharing provider for enterprises. Box is headquartered in Redwood City, California.","news_type":1},"isVote":1,"tweetType":1,"viewCount":213,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879762019,"gmtCreate":1636774574138,"gmtModify":1636774574138,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"Like!!","listText":"Like!!","text":"Like!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879762019","repostId":"1102251183","repostType":2,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":300,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605095912,"gmtCreate":1639091102229,"gmtModify":1639091102292,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"thanks","listText":"thanks","text":"thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605095912","repostId":"2190964556","repostType":2,"repost":{"id":"2190964556","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639090919,"share":"https://www.laohu8.com/m/news/2190964556?lang=&edition=full","pubTime":"2021-12-10 07:01","market":"us","language":"en","title":"Wall St closes lower ahead of inflation data, Fed meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2190964556","media":"Reuters","summary":"Wall Street closed lower on Thursday as investors banked some profits after three straight days of g","content":"<p>Wall Street closed lower on Thursday as investors banked some profits after three straight days of gains and turned their focus toward upcoming inflation data and how it might influence the Federal Reserve's meeting next week.</p>\n<p>The Nasdaq was down more sharply than the S&amp;P 500 while the Dow was virtually flat, ending down less than 1 point.</p>\n<p>Investors were in a waiting game ahead of U.S. consumer prices index inflation data due Friday morning. A higher-than-expected reading would strengthen the case for a policy tightening decision at the U.S. central bank's meeting.</p>\n<p>In the first three days of the week, the Nasdaq rallied 4.7%, the S&amp;P advanced 3.6% and the Dow gained 3.4% as fears abated about the latest coronavirus variant Omicron.</p>\n<p>\"We had a rip roaring rally. There's still nervous people out there,\" said Dennis Dick, head of markets structure, proprietary trader at Bright Trading LLC in Las Vegas.</p>\n<p>\"We'd a Omicron relief rally but the underlying problem still remains, that the Fed's taking the punchbowl away.\"</p>\n<p>Joe Quinlan, chief market strategist for the CIO office of Bank of America, said investors may be taking profits and pausing buying after the three days of gains.</p>\n<p>\"Also there may be a little risk-off trade ahead of the CPI number on Friday,\" he said. \"If it comes in hotter than expected it really shines the light and the focus on the Fed meeting. The pressure would build on the Fed for a faster tapering.\"</p>\n<p>Fed Chair Powell signaled last week that the meeting would include a discussion about a faster tapering of bond-buying.</p>\n<p>\"It would reaffirm in many people's minds that the Fed is behind the curve,\" said Quinlan.</p>\n<p>If the inflation number implies a need to hike rates faster, this \"would put pressure on technology and give a bid to cyclicals\" he said.</p>\n<p>\"You'd want to buy the companies that could pass on these higher costs to consumers. That undermines the growth story. You want to own more cyclicals and value than growth,\" said Quinlan.</p>\n<p>A Reuters poll of economists predicted the Fed would raise rates by 25 basis points to 0.25-0.50% in the third quarter of next year. However, most saw the risk that a hike comes even sooner.</p>\n<p>The Dow Jones Industrial Average fell 0.06 points to 35,754.69, the S&amp;P 500 lost 33.76 points, or 0.72%, to 4,667.45 and the Nasdaq Composite dropped 269.62 points, or 1.71%, to 15,517.37.</p>\n<p>Nine of the 11 major S&amp;P sectors declined, with consumer discretionary down 1.7%, losing the most and real estate , down 1.4%, and information technology&nbsp;falling 1%, showing the next biggest losses.</p>\n<p>The only sector gainers were healthcare up 0.2% and consumer staples which clung to a 0.06% advance.</p>\n<p>Healthcare was boosted by a CVS Health Corp share gain of 4.5% after the drugstore operator raised its 2021 profit forecast.</p>\n<p>In consumer staples, heavyweight electric car maker Tesla&nbsp;was the biggest percentage decliner, falling 6%.</p>\n<p>Markets have seesawed since late November when the Omicron variant was discovered. Investors worried it could upend a global recovery at a time of surging inflation with Fed commentary exacerbating volatility.</p>\n<p>Wall Street's main indexes were supported this week by an update showing Pfizer and BioNTech's vaccine offered some protection against the Omicron variant.</p>\n<p>Data showed initial claims for state unemployment benefits tumbled 43,000 last week to 184,000, the lowest level in more than 52 years.</p>\n<p>GameStop Corp fell 10% after the video game retailer popular among retail investors said it was issued a subpoena by the U.S. securities regulator back in August for documents on an investigation into its share trading activity.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 3.03-to-1 ratio; on Nasdaq, a 3.05-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 23 new 52-week highs and 1 new lows; the Nasdaq Composite recorded 34 new highs and 68 new lows.</p>\n<p>On U.S. exchanges 9.75 billion shares changed hands compared with the 11.41 billion average for the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St closes lower ahead of inflation data, Fed meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St closes lower ahead of inflation data, Fed meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-10 07:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Wall Street closed lower on Thursday as investors banked some profits after three straight days of gains and turned their focus toward upcoming inflation data and how it might influence the Federal Reserve's meeting next week.</p>\n<p>The Nasdaq was down more sharply than the S&amp;P 500 while the Dow was virtually flat, ending down less than 1 point.</p>\n<p>Investors were in a waiting game ahead of U.S. consumer prices index inflation data due Friday morning. A higher-than-expected reading would strengthen the case for a policy tightening decision at the U.S. central bank's meeting.</p>\n<p>In the first three days of the week, the Nasdaq rallied 4.7%, the S&amp;P advanced 3.6% and the Dow gained 3.4% as fears abated about the latest coronavirus variant Omicron.</p>\n<p>\"We had a rip roaring rally. There's still nervous people out there,\" said Dennis Dick, head of markets structure, proprietary trader at Bright Trading LLC in Las Vegas.</p>\n<p>\"We'd a Omicron relief rally but the underlying problem still remains, that the Fed's taking the punchbowl away.\"</p>\n<p>Joe Quinlan, chief market strategist for the CIO office of Bank of America, said investors may be taking profits and pausing buying after the three days of gains.</p>\n<p>\"Also there may be a little risk-off trade ahead of the CPI number on Friday,\" he said. \"If it comes in hotter than expected it really shines the light and the focus on the Fed meeting. The pressure would build on the Fed for a faster tapering.\"</p>\n<p>Fed Chair Powell signaled last week that the meeting would include a discussion about a faster tapering of bond-buying.</p>\n<p>\"It would reaffirm in many people's minds that the Fed is behind the curve,\" said Quinlan.</p>\n<p>If the inflation number implies a need to hike rates faster, this \"would put pressure on technology and give a bid to cyclicals\" he said.</p>\n<p>\"You'd want to buy the companies that could pass on these higher costs to consumers. That undermines the growth story. You want to own more cyclicals and value than growth,\" said Quinlan.</p>\n<p>A Reuters poll of economists predicted the Fed would raise rates by 25 basis points to 0.25-0.50% in the third quarter of next year. However, most saw the risk that a hike comes even sooner.</p>\n<p>The Dow Jones Industrial Average fell 0.06 points to 35,754.69, the S&amp;P 500 lost 33.76 points, or 0.72%, to 4,667.45 and the Nasdaq Composite dropped 269.62 points, or 1.71%, to 15,517.37.</p>\n<p>Nine of the 11 major S&amp;P sectors declined, with consumer discretionary down 1.7%, losing the most and real estate , down 1.4%, and information technology&nbsp;falling 1%, showing the next biggest losses.</p>\n<p>The only sector gainers were healthcare up 0.2% and consumer staples which clung to a 0.06% advance.</p>\n<p>Healthcare was boosted by a CVS Health Corp share gain of 4.5% after the drugstore operator raised its 2021 profit forecast.</p>\n<p>In consumer staples, heavyweight electric car maker Tesla&nbsp;was the biggest percentage decliner, falling 6%.</p>\n<p>Markets have seesawed since late November when the Omicron variant was discovered. Investors worried it could upend a global recovery at a time of surging inflation with Fed commentary exacerbating volatility.</p>\n<p>Wall Street's main indexes were supported this week by an update showing Pfizer and BioNTech's vaccine offered some protection against the Omicron variant.</p>\n<p>Data showed initial claims for state unemployment benefits tumbled 43,000 last week to 184,000, the lowest level in more than 52 years.</p>\n<p>GameStop Corp fell 10% after the video game retailer popular among retail investors said it was issued a subpoena by the U.S. securities regulator back in August for documents on an investigation into its share trading activity.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 3.03-to-1 ratio; on Nasdaq, a 3.05-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 23 new 52-week highs and 1 new lows; the Nasdaq Composite recorded 34 new highs and 68 new lows.</p>\n<p>On U.S. exchanges 9.75 billion shares changed hands compared with the 11.41 billion average for the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4099":"汽车制造商","TSLA":"特斯拉","BK4548":"巴美列捷福持仓","DJX":"1/100道琼斯","SQQQ":"纳指三倍做空ETF","SDOW":"道指三倍做空ETF-ProShares","QQQ":"纳指100ETF","DXD":"道指两倍做空ETF","BK4534":"瑞士信贷持仓","BK4555":"新能源车","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4196":"保健护理服务","QID":"纳指两倍做空ETF","GME":"游戏驿站","CPI":"IQ Real Return ETF","BK4527":"明星科技股","DDM":"道指两倍做多ETF","CVS":"西维斯健康","TQQQ":"纳指三倍做多ETF","BK4550":"红杉资本持仓",".DJI":"道琼斯","PFE":"辉瑞","BK4076":"电脑与电子产品零售",".IXIC":"NASDAQ Composite","BK4504":"桥水持仓","BK4551":"寇图资本持仓","DOG":"道指反向ETF",".SPX":"S&P 500 Index","BK4547":"WSB热门概念","PSQ":"纳指反向ETF","QLD":"纳指两倍做多ETF","UDOW":"道指三倍做多ETF-ProShares"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190964556","content_text":"Wall Street closed lower on Thursday as investors banked some profits after three straight days of gains and turned their focus toward upcoming inflation data and how it might influence the Federal Reserve's meeting next week.\nThe Nasdaq was down more sharply than the S&P 500 while the Dow was virtually flat, ending down less than 1 point.\nInvestors were in a waiting game ahead of U.S. consumer prices index inflation data due Friday morning. A higher-than-expected reading would strengthen the case for a policy tightening decision at the U.S. central bank's meeting.\nIn the first three days of the week, the Nasdaq rallied 4.7%, the S&P advanced 3.6% and the Dow gained 3.4% as fears abated about the latest coronavirus variant Omicron.\n\"We had a rip roaring rally. There's still nervous people out there,\" said Dennis Dick, head of markets structure, proprietary trader at Bright Trading LLC in Las Vegas.\n\"We'd a Omicron relief rally but the underlying problem still remains, that the Fed's taking the punchbowl away.\"\nJoe Quinlan, chief market strategist for the CIO office of Bank of America, said investors may be taking profits and pausing buying after the three days of gains.\n\"Also there may be a little risk-off trade ahead of the CPI number on Friday,\" he said. \"If it comes in hotter than expected it really shines the light and the focus on the Fed meeting. The pressure would build on the Fed for a faster tapering.\"\nFed Chair Powell signaled last week that the meeting would include a discussion about a faster tapering of bond-buying.\n\"It would reaffirm in many people's minds that the Fed is behind the curve,\" said Quinlan.\nIf the inflation number implies a need to hike rates faster, this \"would put pressure on technology and give a bid to cyclicals\" he said.\n\"You'd want to buy the companies that could pass on these higher costs to consumers. That undermines the growth story. You want to own more cyclicals and value than growth,\" said Quinlan.\nA Reuters poll of economists predicted the Fed would raise rates by 25 basis points to 0.25-0.50% in the third quarter of next year. However, most saw the risk that a hike comes even sooner.\nThe Dow Jones Industrial Average fell 0.06 points to 35,754.69, the S&P 500 lost 33.76 points, or 0.72%, to 4,667.45 and the Nasdaq Composite dropped 269.62 points, or 1.71%, to 15,517.37.\nNine of the 11 major S&P sectors declined, with consumer discretionary down 1.7%, losing the most and real estate , down 1.4%, and information technology falling 1%, showing the next biggest losses.\nThe only sector gainers were healthcare up 0.2% and consumer staples which clung to a 0.06% advance.\nHealthcare was boosted by a CVS Health Corp share gain of 4.5% after the drugstore operator raised its 2021 profit forecast.\nIn consumer staples, heavyweight electric car maker Tesla was the biggest percentage decliner, falling 6%.\nMarkets have seesawed since late November when the Omicron variant was discovered. Investors worried it could upend a global recovery at a time of surging inflation with Fed commentary exacerbating volatility.\nWall Street's main indexes were supported this week by an update showing Pfizer and BioNTech's vaccine offered some protection against the Omicron variant.\nData showed initial claims for state unemployment benefits tumbled 43,000 last week to 184,000, the lowest level in more than 52 years.\nGameStop Corp fell 10% after the video game retailer popular among retail investors said it was issued a subpoena by the U.S. securities regulator back in August for documents on an investigation into its share trading activity.\nDeclining issues outnumbered advancing ones on the NYSE by a 3.03-to-1 ratio; on Nasdaq, a 3.05-to-1 ratio favored decliners.\nThe S&P 500 posted 23 new 52-week highs and 1 new lows; the Nasdaq Composite recorded 34 new highs and 68 new lows.\nOn U.S. exchanges 9.75 billion shares changed hands compared with the 11.41 billion average for the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":618,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606114376,"gmtCreate":1638842490925,"gmtModify":1638842636823,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"thanks","listText":"thanks","text":"thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606114376","repostId":"1165217690","repostType":2,"repost":{"id":"1165217690","kind":"news","pubTimestamp":1638841605,"share":"https://www.laohu8.com/m/news/1165217690?lang=&edition=full","pubTime":"2021-12-07 09:46","market":"us","language":"en","title":"Vaccine Stocks: Why MRNA, BNTX, NVAX, PFE Stocks Are Stumbling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1165217690","media":"InvestorPlace","summary":"Good news for public health can sometimes mean bad news for vaccine stocks. Today reminded us exactl","content":"<p>Good news for public health can sometimes mean bad news for vaccine stocks. Today reminded us exactly why. After more than a week of ominous reports on the omicron virus and mounting speculation about its severity, yesterday brought some welcome news. Dr. Anthony Fauci, White House chief medical officer and a trusted expert on the virus, stated yesterday that some clear preliminary data was finally starting to emerge on the severity of the new variant and that so far, the results looked“encouraging.”</p>\n<p>What’s Happening With Vaccine Stocks</p>\n<p>Since news of the new variant first began dominating media airwaves, vaccine producers have been scrambling to be the first to address the new Covid-19 strain that threatened to undo the work that sent their stocks up earlier this year. Today has seen all the prominent names among vaccine stocks plunge across the board. While this isn’t strictly due to Dr. Fauci’s comments, it’s possible that the demand for new vaccine innovations and treatments may not be as great as we feared only a few days ago.</p>\n<p><b>BioNTech</b>&nbsp;(NASDAQ:<b><u>BNTX</u></b>) has suffered the worst declines of the day among vaccine stocks, with shares down almost 19% as of this writing. Next in line is&nbsp;<b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>), which has fallen more than 13%. Then,&nbsp;<b>Novavax’s</b>(NASDAQ:<b><u>NVAX</u></b>)declines come in just shy of 12%. Rounding out the pack is&nbsp;<b>Pfizer</b>(NYSE:<b><u>PFE</u></b>), which is in the red by just over 5% as trading winds to a close today.</p>\n<p>Why It Matters</p>\n<p>The clearest indication we should take from today’s events is that market mentality is shifting. This is evidenced by the performances we’ve seen not just from vaccine stocks but from other sectors that were differently affected by the spreading variant news. As&nbsp;<i>InvestorPlace’</i>s Shrey Dua reports,&nbsp;cruise ship stocks&nbsp;such as&nbsp;<b>Royal Caribbean</b>(NYSE:<b><u>RCL</u></b>) and&nbsp;<b>Carnival</b>(NYSE:<b><u>CCL</u></b>) are back in the green today after a troubling week of variant concerns. The same can be said for airline stocks, as names such as&nbsp;<b>Delta</b>&nbsp;(NYSE:<b><u>DAL</u></b>) and&nbsp;<b>Southwest</b>&nbsp;(NYSE:<b><u>LUV</u></b>) have gained some altitude today.</p>\n<p>Of course, it’s too soon to tell what the future will look like. The preliminary results upon which Dr. Fauci commented are exactly that — preliminary. Scientists and medical researchers still have plenty of research to do before they will be able outline a bigger picture. Dr. Fauci was careful to add that while there does not seem to be a “great degree of severity” to the spreading variant, it is still too early for any definitive conclusions to be reached. Omicron is still very much a variant of concern.</p>\n<p>What It Means</p>\n<p>Even if the variant does not end up posing as serious a threat to highly vaccinated countries as has been speculated, the need for vaccines isn’t going to go away. Fear of the variant has spiked&nbsp;demand&nbsp;for vaccinations in the U.S., and many countries are still struggling to get more of their populations partially or fully vaccinated. The industry landscape may not end up looking quite as bleak close to home as some of us have feared. However, that doesn’t mean that the demand for vaccines won’t be increasing throughout the months ahead.</p>\n<p>This news certainly doesn’t mean that a bearish play on vaccine stocks is advisable. Far from it, in fact. Novavax has an&nbsp;important catalyst&nbsp;rapidly approaching as the World Health Organization (WHO) considers granting it emergency use authorization. More than likely, vaccine stocks will be quick to rebound.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Stocks: Why MRNA, BNTX, NVAX, PFE Stocks Are Stumbling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Stocks: Why MRNA, BNTX, NVAX, PFE Stocks Are Stumbling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 09:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/vaccine-stocks-why-mrna-bntx-nvax-pfe-stocks-are-stumbling-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Good news for public health can sometimes mean bad news for vaccine stocks. Today reminded us exactly why. After more than a week of ominous reports on the omicron virus and mounting speculation about...</p>\n\n<a href=\"https://investorplace.com/2021/12/vaccine-stocks-why-mrna-bntx-nvax-pfe-stocks-are-stumbling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://investorplace.com/2021/12/vaccine-stocks-why-mrna-bntx-nvax-pfe-stocks-are-stumbling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165217690","content_text":"Good news for public health can sometimes mean bad news for vaccine stocks. Today reminded us exactly why. After more than a week of ominous reports on the omicron virus and mounting speculation about its severity, yesterday brought some welcome news. Dr. Anthony Fauci, White House chief medical officer and a trusted expert on the virus, stated yesterday that some clear preliminary data was finally starting to emerge on the severity of the new variant and that so far, the results looked“encouraging.”\nWhat’s Happening With Vaccine Stocks\nSince news of the new variant first began dominating media airwaves, vaccine producers have been scrambling to be the first to address the new Covid-19 strain that threatened to undo the work that sent their stocks up earlier this year. Today has seen all the prominent names among vaccine stocks plunge across the board. While this isn’t strictly due to Dr. Fauci’s comments, it’s possible that the demand for new vaccine innovations and treatments may not be as great as we feared only a few days ago.\nBioNTech (NASDAQ:BNTX) has suffered the worst declines of the day among vaccine stocks, with shares down almost 19% as of this writing. Next in line is Moderna(NASDAQ:MRNA), which has fallen more than 13%. Then, Novavax’s(NASDAQ:NVAX)declines come in just shy of 12%. Rounding out the pack is Pfizer(NYSE:PFE), which is in the red by just over 5% as trading winds to a close today.\nWhy It Matters\nThe clearest indication we should take from today’s events is that market mentality is shifting. This is evidenced by the performances we’ve seen not just from vaccine stocks but from other sectors that were differently affected by the spreading variant news. As InvestorPlace’s Shrey Dua reports, cruise ship stocks such as Royal Caribbean(NYSE:RCL) and Carnival(NYSE:CCL) are back in the green today after a troubling week of variant concerns. The same can be said for airline stocks, as names such as Delta (NYSE:DAL) and Southwest (NYSE:LUV) have gained some altitude today.\nOf course, it’s too soon to tell what the future will look like. The preliminary results upon which Dr. Fauci commented are exactly that — preliminary. Scientists and medical researchers still have plenty of research to do before they will be able outline a bigger picture. Dr. Fauci was careful to add that while there does not seem to be a “great degree of severity” to the spreading variant, it is still too early for any definitive conclusions to be reached. Omicron is still very much a variant of concern.\nWhat It Means\nEven if the variant does not end up posing as serious a threat to highly vaccinated countries as has been speculated, the need for vaccines isn’t going to go away. Fear of the variant has spiked demand for vaccinations in the U.S., and many countries are still struggling to get more of their populations partially or fully vaccinated. The industry landscape may not end up looking quite as bleak close to home as some of us have feared. However, that doesn’t mean that the demand for vaccines won’t be increasing throughout the months ahead.\nThis news certainly doesn’t mean that a bearish play on vaccine stocks is advisable. Far from it, in fact. Novavax has an important catalyst rapidly approaching as the World Health Organization (WHO) considers granting it emergency use authorization. More than likely, vaccine stocks will be quick to rebound.","news_type":1},"isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876203545,"gmtCreate":1637313763461,"gmtModify":1637314167419,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"grats","listText":"grats","text":"grats","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876203545","repostId":"1143344231","repostType":2,"repost":{"id":"1143344231","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637312557,"share":"https://www.laohu8.com/m/news/1143344231?lang=&edition=full","pubTime":"2021-11-19 17:02","market":"us","language":"en","title":"Longeveron continued to climb over 50% in premarket trading as FDA approved its Lomecel-B for rare pediatric disease designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1143344231","media":"Tiger Newspress","summary":"Longeveron continued to climb over 50% in premarket trading as FDA approved its Lomecel-B for rare p","content":"<p>Longeveron&nbsp;continued&nbsp;to&nbsp;climb&nbsp;over&nbsp;50%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;as&nbsp;FDA&nbsp;approved its Lomecel-B for rare pediatric disease designation.<img src=\"https://static.tigerbbs.com/6b1cd0f83b93e7a6c6bdcdbba2cdbaa6\" tg-width=\"772\" tg-height=\"566\" width=\"100%\" height=\"auto\">The&nbsp;company&nbsp;announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants. Lomecel-B, an investigational allogeneic, bone marrow-derived medicinal signaling cell (MSC) product, is currently being evaluated in a Phase 2 trial.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron continued to climb over 50% in premarket trading as FDA approved its Lomecel-B for rare pediatric disease designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron continued to climb over 50% in premarket trading as FDA approved its Lomecel-B for rare pediatric disease designation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 17:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Longeveron&nbsp;continued&nbsp;to&nbsp;climb&nbsp;over&nbsp;50%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;as&nbsp;FDA&nbsp;approved its Lomecel-B for rare pediatric disease designation.<img src=\"https://static.tigerbbs.com/6b1cd0f83b93e7a6c6bdcdbba2cdbaa6\" tg-width=\"772\" tg-height=\"566\" width=\"100%\" height=\"auto\">The&nbsp;company&nbsp;announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants. Lomecel-B, an investigational allogeneic, bone marrow-derived medicinal signaling cell (MSC) product, is currently being evaluated in a Phase 2 trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143344231","content_text":"Longeveron continued to climb over 50% in premarket trading as FDA approved its Lomecel-B for rare pediatric disease designation.The company announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants. Lomecel-B, an investigational allogeneic, bone marrow-derived medicinal signaling cell (MSC) product, is currently being evaluated in a Phase 2 trial.","news_type":1},"isVote":1,"tweetType":1,"viewCount":435,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690480691,"gmtCreate":1639701311917,"gmtModify":1639701311996,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"😊&nbsp;","listText":"😊&nbsp;","text":"😊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690480691","repostId":"2192920942","repostType":2,"repost":{"id":"2192920942","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639694745,"share":"https://www.laohu8.com/m/news/2192920942?lang=&edition=full","pubTime":"2021-12-17 06:45","market":"us","language":"en","title":"Nasdaq ends sharply lower as investors dump growth stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2192920942","media":"Reuters","summary":"* Fed to end bond purchases, signals rate hikes in 2022\n* Tech is worst among 11 S&P 500 sector inde","content":"<p>* Fed to end bond purchases, signals rate hikes in 2022</p>\n<p>* Tech is worst among 11 S&amp;P 500 sector indexes, financials rally</p>\n<p>* Lennar slips after missing quarterly profit</p>\n<p>* Indexes: Dow -0.08%, S&amp;P 500 -0.87%, Nasdaq -2.47%</p>\n<p>Dec 16 (Reuters) - The Nasdaq ended sharply lower on Thursday as the Federal Reserve's announcement of a faster end to its pandemic-era stimulus pushed investors away from Big Tech and toward more economically sensitive sectors.</p>\n<p>Nvidia,Apple,Microsoft, Amazon&nbsp;and Tesla&nbsp;tumbled between 2.6% and 6.8%, hitting the Nasdaq&nbsp;and the S&amp;P 500, while the Dow Jones Industrial Average declined marginally.</p>\n<p>Most of those heavyweight growth stocks have outperformed the broader market in 2021, with Nvidia up more than 100% year to date.</p>\n<p>The Dow Jones Industrial Average&nbsp;fell 0.08% to end at 35,897.64, while the S&amp;P 500&nbsp;lost 0.87% to 4,668.67.</p>\n<p>The Nasdaq Composite&nbsp;dropped 2.47% to 15,180.44.</p>\n<p>The U.S. central bank said on Wednesday it would end its bond purchases in March and signaled three quarter-percentage-point interest rate hikes by the end of 2022.</p>\n<p>That pleased investors who have increasingly worried about an inflation spike related to the coronavirus pandemic. But on Thursday it contributed to the sell-off in growth stocks.</p>\n<p>The S&amp;P 500 value index&nbsp;climbed 0.7%, while the growth index fell 2.1%, reflecting investors' views that high-growth stocks tend to underperform when interest rates rise. The value index includes stocks seen as more likely to do well during an economic recovery.</p>\n<p>\"You're seeing money come out of growth, as it should. If we are going into an environment where interest rates are going up, growth stocks are going to be less attractive\" said Dennis Dick, a trader at Bright Trading LLC.</p>\n<p>\"There's a lot of uncertainty as we go into 2022... We're going to have a more hawkish Fed that is going to pull away the punch bowl,\" he said.</p>\n<p>Among the 11 major S&amp;P 500 sector indexes, technology&nbsp;slumped 2.9%, while financials&nbsp;rallied 1.2%. Eight of the sectors gained, even as the overall index fell.</p>\n<p>\"The Fed gave the market what it wanted, and today I think investors are turning again to pandemic uncertainty, and they're also cautious going into the end of the year,\" said Lindsey Bell, chief investment strategist at Ally Invest, in Charlotte, North Carolina.</p>\n<p>Recent readings on surging producer and consumer prices, as well as the fast-spreading Omicron variant of the coronavirus, have fueled anxiety. The S&amp;P 500, nonetheless, remains up about 25% in 2021 and it is trading near record highs.</p>\n<p>The CBOE Volatility index, often considered Wall Street's fear gauge, slipped to a three-week low.</p>\n<p>Data showed the number of Americans filing new claims for unemployment benefits increased moderately last week, remaining at levels consistent with tightening labor market conditions.</p>\n<p>Separately, a survey showed production at U.S. factories increased to the highest level in nearly three years in November.</p>\n<p>Lennar Corp&nbsp;fell 4.1% after the homebuilder missed analysts' estimates for quarterly profit as pandemic-led supply chain issues pushed lumber costs higher and delayed house deliveries.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.03-to-1 ratio; on Nasdaq, a 1.93-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 69 new 52-week highs and 3 new lows; the Nasdaq Composite recorded 43 new highs and 184 new lows.</p>\n<p>Volume on U.S. exchanges was 11.6 billion shares, in line with the average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq ends sharply lower as investors dump growth stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq ends sharply lower as investors dump growth stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-17 06:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Fed to end bond purchases, signals rate hikes in 2022</p>\n<p>* Tech is worst among 11 S&amp;P 500 sector indexes, financials rally</p>\n<p>* Lennar slips after missing quarterly profit</p>\n<p>* Indexes: Dow -0.08%, S&amp;P 500 -0.87%, Nasdaq -2.47%</p>\n<p>Dec 16 (Reuters) - The Nasdaq ended sharply lower on Thursday as the Federal Reserve's announcement of a faster end to its pandemic-era stimulus pushed investors away from Big Tech and toward more economically sensitive sectors.</p>\n<p>Nvidia,Apple,Microsoft, Amazon&nbsp;and Tesla&nbsp;tumbled between 2.6% and 6.8%, hitting the Nasdaq&nbsp;and the S&amp;P 500, while the Dow Jones Industrial Average declined marginally.</p>\n<p>Most of those heavyweight growth stocks have outperformed the broader market in 2021, with Nvidia up more than 100% year to date.</p>\n<p>The Dow Jones Industrial Average&nbsp;fell 0.08% to end at 35,897.64, while the S&amp;P 500&nbsp;lost 0.87% to 4,668.67.</p>\n<p>The Nasdaq Composite&nbsp;dropped 2.47% to 15,180.44.</p>\n<p>The U.S. central bank said on Wednesday it would end its bond purchases in March and signaled three quarter-percentage-point interest rate hikes by the end of 2022.</p>\n<p>That pleased investors who have increasingly worried about an inflation spike related to the coronavirus pandemic. But on Thursday it contributed to the sell-off in growth stocks.</p>\n<p>The S&amp;P 500 value index&nbsp;climbed 0.7%, while the growth index fell 2.1%, reflecting investors' views that high-growth stocks tend to underperform when interest rates rise. The value index includes stocks seen as more likely to do well during an economic recovery.</p>\n<p>\"You're seeing money come out of growth, as it should. If we are going into an environment where interest rates are going up, growth stocks are going to be less attractive\" said Dennis Dick, a trader at Bright Trading LLC.</p>\n<p>\"There's a lot of uncertainty as we go into 2022... We're going to have a more hawkish Fed that is going to pull away the punch bowl,\" he said.</p>\n<p>Among the 11 major S&amp;P 500 sector indexes, technology&nbsp;slumped 2.9%, while financials&nbsp;rallied 1.2%. Eight of the sectors gained, even as the overall index fell.</p>\n<p>\"The Fed gave the market what it wanted, and today I think investors are turning again to pandemic uncertainty, and they're also cautious going into the end of the year,\" said Lindsey Bell, chief investment strategist at Ally Invest, in Charlotte, North Carolina.</p>\n<p>Recent readings on surging producer and consumer prices, as well as the fast-spreading Omicron variant of the coronavirus, have fueled anxiety. The S&amp;P 500, nonetheless, remains up about 25% in 2021 and it is trading near record highs.</p>\n<p>The CBOE Volatility index, often considered Wall Street's fear gauge, slipped to a three-week low.</p>\n<p>Data showed the number of Americans filing new claims for unemployment benefits increased moderately last week, remaining at levels consistent with tightening labor market conditions.</p>\n<p>Separately, a survey showed production at U.S. factories increased to the highest level in nearly three years in November.</p>\n<p>Lennar Corp&nbsp;fell 4.1% after the homebuilder missed analysts' estimates for quarterly profit as pandemic-led supply chain issues pushed lumber costs higher and delayed house deliveries.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.03-to-1 ratio; on Nasdaq, a 1.93-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 69 new 52-week highs and 3 new lows; the Nasdaq Composite recorded 43 new highs and 184 new lows.</p>\n<p>Volume on U.S. exchanges was 11.6 billion shares, in line with the average over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SSO":"两倍做多标普500ETF","BK4099":"汽车制造商","TSLA":"特斯拉","BK4549":"软银资本持仓","BK4088":"住宅建筑","BK4548":"巴美列捷福持仓","NVDA":"英伟达","SPXU":"三倍做空标普500ETF","SQQQ":"纳指三倍做空ETF","AMZN":"亚马逊","BK4515":"5G概念","BK4554":"元宇宙及AR概念","SDOW":"道指三倍做空ETF-ProShares","OEF":"标普100指数ETF-iShares","BK4553":"喜马拉雅资本持仓","QQQ":"纳指100ETF","DXD":"道指两倍做空ETF","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","LEN":"莱纳建筑公司","SDS":"两倍做空标普500ETF","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4524":"宅经济概念","BK4501":"段永平概念","BK4543":"AI","BK4538":"云计算","BK4527":"明星科技股","DDM":"道指两倍做多ETF","BK4559":"巴菲特持仓","TQQQ":"纳指三倍做多ETF",".DJI":"道琼斯","UDOW":"道指三倍做多ETF-ProShares","BK4503":"景林资产持仓","SH":"标普500反向ETF","IVV":"标普500指数ETF",".IXIC":"NASDAQ Composite","BK4551":"寇图资本持仓","DOG":"道指反向ETF","BK4504":"桥水持仓","OEX":"标普100",".SPX":"S&P 500 Index","BK4505":"高瓴资本持仓","PSQ":"纳指反向ETF","BK4561":"索罗斯持仓","UPRO":"三倍做多标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192920942","content_text":"* Fed to end bond purchases, signals rate hikes in 2022\n* Tech is worst among 11 S&P 500 sector indexes, financials rally\n* Lennar slips after missing quarterly profit\n* Indexes: Dow -0.08%, S&P 500 -0.87%, Nasdaq -2.47%\nDec 16 (Reuters) - The Nasdaq ended sharply lower on Thursday as the Federal Reserve's announcement of a faster end to its pandemic-era stimulus pushed investors away from Big Tech and toward more economically sensitive sectors.\nNvidia,Apple,Microsoft, Amazon and Tesla tumbled between 2.6% and 6.8%, hitting the Nasdaq and the S&P 500, while the Dow Jones Industrial Average declined marginally.\nMost of those heavyweight growth stocks have outperformed the broader market in 2021, with Nvidia up more than 100% year to date.\nThe Dow Jones Industrial Average fell 0.08% to end at 35,897.64, while the S&P 500 lost 0.87% to 4,668.67.\nThe Nasdaq Composite dropped 2.47% to 15,180.44.\nThe U.S. central bank said on Wednesday it would end its bond purchases in March and signaled three quarter-percentage-point interest rate hikes by the end of 2022.\nThat pleased investors who have increasingly worried about an inflation spike related to the coronavirus pandemic. But on Thursday it contributed to the sell-off in growth stocks.\nThe S&P 500 value index climbed 0.7%, while the growth index fell 2.1%, reflecting investors' views that high-growth stocks tend to underperform when interest rates rise. The value index includes stocks seen as more likely to do well during an economic recovery.\n\"You're seeing money come out of growth, as it should. If we are going into an environment where interest rates are going up, growth stocks are going to be less attractive\" said Dennis Dick, a trader at Bright Trading LLC.\n\"There's a lot of uncertainty as we go into 2022... We're going to have a more hawkish Fed that is going to pull away the punch bowl,\" he said.\nAmong the 11 major S&P 500 sector indexes, technology slumped 2.9%, while financials rallied 1.2%. Eight of the sectors gained, even as the overall index fell.\n\"The Fed gave the market what it wanted, and today I think investors are turning again to pandemic uncertainty, and they're also cautious going into the end of the year,\" said Lindsey Bell, chief investment strategist at Ally Invest, in Charlotte, North Carolina.\nRecent readings on surging producer and consumer prices, as well as the fast-spreading Omicron variant of the coronavirus, have fueled anxiety. The S&P 500, nonetheless, remains up about 25% in 2021 and it is trading near record highs.\nThe CBOE Volatility index, often considered Wall Street's fear gauge, slipped to a three-week low.\nData showed the number of Americans filing new claims for unemployment benefits increased moderately last week, remaining at levels consistent with tightening labor market conditions.\nSeparately, a survey showed production at U.S. factories increased to the highest level in nearly three years in November.\nLennar Corp fell 4.1% after the homebuilder missed analysts' estimates for quarterly profit as pandemic-led supply chain issues pushed lumber costs higher and delayed house deliveries.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.03-to-1 ratio; on Nasdaq, a 1.93-to-1 ratio favored decliners.\nThe S&P 500 posted 69 new 52-week highs and 3 new lows; the Nasdaq Composite recorded 43 new highs and 184 new lows.\nVolume on U.S. exchanges was 11.6 billion shares, in line with the average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":983,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875895158,"gmtCreate":1637630310478,"gmtModify":1637630310478,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"go go go!!","listText":"go go go!!","text":"go go go!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875895158","repostId":"1144786882","repostType":2,"repost":{"id":"1144786882","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1637627337,"share":"https://www.laohu8.com/m/news/1144786882?lang=&edition=full","pubTime":"2021-11-23 08:28","market":"us","language":"en","title":"Can Apple Close Above The All-Time Highs This Week? Option Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=1144786882","media":"Benzinga","summary":"What Happened:Apple Inc is having a volatile day, initially up over 2.5% but having since lost all o","content":"<p><b>What Happened:Apple Inc</b>&nbsp;is having a volatile day, initially up over 2.5%&nbsp;but having since lost all of those gains over the last two hours of trading.</p>\n<p>Trading activity has been strong with over 104 million shares on the day versus the 10-day average of 78 million. The recent sell-off late in the session might be due to supply constraints out of Asia for the upcoming holiday shopping season.</p>\n<p>But what is fascinating is the heavy level of options activity in the stock today with&nbsp;<b>over 2.73 million contracts traded on the day</b>&nbsp;(see below).</p>\n<p><img src=\"https://static.tigerbbs.com/1a3445e396564690250472543787b2dd\" tg-width=\"1002\" tg-height=\"277\" width=\"100%\" height=\"auto\"></p>\n<p><b>Why It Matters:</b>Prior to Monday, Apple had approximately 4.1 million calls and 3.3 million puts for a total of 7.4 million options. Thus, today's 2.7+ million options represent&nbsp;<b>a massive 36% increase in options in one day.</b></p>\n<p>Any time a stock trades 36% of the total options in one day, it suggests option traders are highly active in the stock. And considering 73% of the options traded were calls, it suggests option traders have a strong bullish bias.</p>\n<p><b>What's Next:</b>&nbsp;About half of the option flows today were short-dated (expiring Friday) with the largest concentration of strikes between $160 and $170 (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/fdaae290e3e5538e2f6697fe9cbc40e9\" tg-width=\"1105\" tg-height=\"319\" width=\"100%\" height=\"auto\"></p>\n<p>The short-dated calls suggest option traders are targeting a range between $160 and $170 for the week. However, with the strong sell-off into the close, the stock could probe below the $160 strike.</p>\n<p>If Apple loses the $160 level, there is solid open interest down to the $155 strike, but falls off materially below that, so any sharp moves below here could represent a bigger selloff in the stock.</p>\n<p>Meanwhile, if the stock can break the all-time highs just above $165, there is potentially room for a move up towards the $175 level.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Apple Close Above The All-Time Highs This Week? Option Analysis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Apple Close Above The All-Time Highs This Week? Option Analysis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-11-23 08:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>What Happened:Apple Inc</b>&nbsp;is having a volatile day, initially up over 2.5%&nbsp;but having since lost all of those gains over the last two hours of trading.</p>\n<p>Trading activity has been strong with over 104 million shares on the day versus the 10-day average of 78 million. The recent sell-off late in the session might be due to supply constraints out of Asia for the upcoming holiday shopping season.</p>\n<p>But what is fascinating is the heavy level of options activity in the stock today with&nbsp;<b>over 2.73 million contracts traded on the day</b>&nbsp;(see below).</p>\n<p><img src=\"https://static.tigerbbs.com/1a3445e396564690250472543787b2dd\" tg-width=\"1002\" tg-height=\"277\" width=\"100%\" height=\"auto\"></p>\n<p><b>Why It Matters:</b>Prior to Monday, Apple had approximately 4.1 million calls and 3.3 million puts for a total of 7.4 million options. Thus, today's 2.7+ million options represent&nbsp;<b>a massive 36% increase in options in one day.</b></p>\n<p>Any time a stock trades 36% of the total options in one day, it suggests option traders are highly active in the stock. And considering 73% of the options traded were calls, it suggests option traders have a strong bullish bias.</p>\n<p><b>What's Next:</b>&nbsp;About half of the option flows today were short-dated (expiring Friday) with the largest concentration of strikes between $160 and $170 (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/fdaae290e3e5538e2f6697fe9cbc40e9\" tg-width=\"1105\" tg-height=\"319\" width=\"100%\" height=\"auto\"></p>\n<p>The short-dated calls suggest option traders are targeting a range between $160 and $170 for the week. However, with the strong sell-off into the close, the stock could probe below the $160 strike.</p>\n<p>If Apple loses the $160 level, there is solid open interest down to the $155 strike, but falls off materially below that, so any sharp moves below here could represent a bigger selloff in the stock.</p>\n<p>Meanwhile, if the stock can break the all-time highs just above $165, there is potentially room for a move up towards the $175 level.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144786882","content_text":"What Happened:Apple Inc is having a volatile day, initially up over 2.5% but having since lost all of those gains over the last two hours of trading.\nTrading activity has been strong with over 104 million shares on the day versus the 10-day average of 78 million. The recent sell-off late in the session might be due to supply constraints out of Asia for the upcoming holiday shopping season.\nBut what is fascinating is the heavy level of options activity in the stock today with over 2.73 million contracts traded on the day (see below).\n\nWhy It Matters:Prior to Monday, Apple had approximately 4.1 million calls and 3.3 million puts for a total of 7.4 million options. Thus, today's 2.7+ million options represent a massive 36% increase in options in one day.\nAny time a stock trades 36% of the total options in one day, it suggests option traders are highly active in the stock. And considering 73% of the options traded were calls, it suggests option traders have a strong bullish bias.\nWhat's Next: About half of the option flows today were short-dated (expiring Friday) with the largest concentration of strikes between $160 and $170 (image below).\n\nThe short-dated calls suggest option traders are targeting a range between $160 and $170 for the week. However, with the strong sell-off into the close, the stock could probe below the $160 strike.\nIf Apple loses the $160 level, there is solid open interest down to the $155 strike, but falls off materially below that, so any sharp moves below here could represent a bigger selloff in the stock.\nMeanwhile, if the stock can break the all-time highs just above $165, there is potentially room for a move up towards the $175 level.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1028,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878301207,"gmtCreate":1637144617104,"gmtModify":1637144617104,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878301207","repostId":"1103932041","repostType":2,"repost":{"id":"1103932041","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637140078,"share":"https://www.laohu8.com/m/news/1103932041?lang=&edition=full","pubTime":"2021-11-17 17:07","market":"us","language":"en","title":"Tesla shares rose 1.4% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1103932041","media":"Tiger Newspress","summary":"Tesla shares rose 1.4% in premarket trading although Musk exercised more options, sold $973 million ","content":"<p>Tesla shares rose 1.4% in premarket trading&nbsp;although&nbsp;Musk exercised more options, sold $973 million for taxes.</p>\n<p><img src=\"https://static.tigerbbs.com/606f9df440d66783c7b5ea7dc15676df\" tg-width=\"850\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p>\n<p>Tesla Chief Executive Elon Musk sold another $973 million in stock to pay taxes after exercising options on Tuesday, filings showed after the electric vehicle maker's shares rebounded during regular trade.</p>\n<p>Musk acquired 2.1 million shares worth $2.2 billion at the Tuesday closing price and sold 934,091 for $973 million to pay taxes, the SEC filings showed.</p>\n<p>In a sector surge spearheaded by Rivian Automotive Inc&nbsp;and Lucid Group Inc, Tesla Inc&nbsp;rose 4.1% to close at $1,054.73, leaving its market capitalization down about $187 billion since before Muskbegan selling shareslast week.</p>\n<p>Rivian's stock jumped 15%, with the EV maker now up over 120% since its initial public offer last Wednesday.</p>\n<p>Rivian disclosed in a filing on Tuesday that its underwriters bought 22.95 million additional shares, boosting the total size of the IPO. Including those shares, Rivian's market capitalization rose to $153 billion, overtaking Volkswagen AG(VOWG_p.DE)by $14 billion and making the Irvine, California, company the world's third-most valuable carmaker.</p>\n<p>Lucid surged nearly 24% after it said reservations for its cars rose to 13,000 in the third quarter and that it is confident it will produce 20,000 of its upcoming Lucid Air sedans in 2022.</p>\n<p>The gain in Lucid's shares elevated its stock market value to $90 billion, overtaking Ford Motor Co(F.N)and leaving it $1 billion short of General Motors Co.</p>\n<p>Over the past week, Musk has sold about 8.2 million Tesla shares for around $8.8 billion. Those sales fulfill almost half of his pledge on Twitter to sell 10% of his stake in Tesla.</p>\n<p>Musk began selling shares last week after floating the idea in aTwitter poll.</p>\n<p>With electric-car makers increasingly in demand on Wall Street, Tesla's stock has surged more than 150% in the past 12 months.</p>\n<p>\"There's still plenty of buying interest because I still think ultimately investors are viewing this as a phase and viewing pullbacks as an opportunity,\" said Craig Erlam, senior market economist at OANDA.</p>\n<p>\"If you ask me where the share price is going to be six months from now, 12 months from now? I'd say it's more likely to be 20% higher than 20% lower.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla shares rose 1.4% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla shares rose 1.4% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-17 17:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tesla shares rose 1.4% in premarket trading&nbsp;although&nbsp;Musk exercised more options, sold $973 million for taxes.</p>\n<p><img src=\"https://static.tigerbbs.com/606f9df440d66783c7b5ea7dc15676df\" tg-width=\"850\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p>\n<p>Tesla Chief Executive Elon Musk sold another $973 million in stock to pay taxes after exercising options on Tuesday, filings showed after the electric vehicle maker's shares rebounded during regular trade.</p>\n<p>Musk acquired 2.1 million shares worth $2.2 billion at the Tuesday closing price and sold 934,091 for $973 million to pay taxes, the SEC filings showed.</p>\n<p>In a sector surge spearheaded by Rivian Automotive Inc&nbsp;and Lucid Group Inc, Tesla Inc&nbsp;rose 4.1% to close at $1,054.73, leaving its market capitalization down about $187 billion since before Muskbegan selling shareslast week.</p>\n<p>Rivian's stock jumped 15%, with the EV maker now up over 120% since its initial public offer last Wednesday.</p>\n<p>Rivian disclosed in a filing on Tuesday that its underwriters bought 22.95 million additional shares, boosting the total size of the IPO. Including those shares, Rivian's market capitalization rose to $153 billion, overtaking Volkswagen AG(VOWG_p.DE)by $14 billion and making the Irvine, California, company the world's third-most valuable carmaker.</p>\n<p>Lucid surged nearly 24% after it said reservations for its cars rose to 13,000 in the third quarter and that it is confident it will produce 20,000 of its upcoming Lucid Air sedans in 2022.</p>\n<p>The gain in Lucid's shares elevated its stock market value to $90 billion, overtaking Ford Motor Co(F.N)and leaving it $1 billion short of General Motors Co.</p>\n<p>Over the past week, Musk has sold about 8.2 million Tesla shares for around $8.8 billion. Those sales fulfill almost half of his pledge on Twitter to sell 10% of his stake in Tesla.</p>\n<p>Musk began selling shares last week after floating the idea in aTwitter poll.</p>\n<p>With electric-car makers increasingly in demand on Wall Street, Tesla's stock has surged more than 150% in the past 12 months.</p>\n<p>\"There's still plenty of buying interest because I still think ultimately investors are viewing this as a phase and viewing pullbacks as an opportunity,\" said Craig Erlam, senior market economist at OANDA.</p>\n<p>\"If you ask me where the share price is going to be six months from now, 12 months from now? I'd say it's more likely to be 20% higher than 20% lower.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103932041","content_text":"Tesla shares rose 1.4% in premarket trading although Musk exercised more options, sold $973 million for taxes.\n\nTesla Chief Executive Elon Musk sold another $973 million in stock to pay taxes after exercising options on Tuesday, filings showed after the electric vehicle maker's shares rebounded during regular trade.\nMusk acquired 2.1 million shares worth $2.2 billion at the Tuesday closing price and sold 934,091 for $973 million to pay taxes, the SEC filings showed.\nIn a sector surge spearheaded by Rivian Automotive Inc and Lucid Group Inc, Tesla Inc rose 4.1% to close at $1,054.73, leaving its market capitalization down about $187 billion since before Muskbegan selling shareslast week.\nRivian's stock jumped 15%, with the EV maker now up over 120% since its initial public offer last Wednesday.\nRivian disclosed in a filing on Tuesday that its underwriters bought 22.95 million additional shares, boosting the total size of the IPO. Including those shares, Rivian's market capitalization rose to $153 billion, overtaking Volkswagen AG(VOWG_p.DE)by $14 billion and making the Irvine, California, company the world's third-most valuable carmaker.\nLucid surged nearly 24% after it said reservations for its cars rose to 13,000 in the third quarter and that it is confident it will produce 20,000 of its upcoming Lucid Air sedans in 2022.\nThe gain in Lucid's shares elevated its stock market value to $90 billion, overtaking Ford Motor Co(F.N)and leaving it $1 billion short of General Motors Co.\nOver the past week, Musk has sold about 8.2 million Tesla shares for around $8.8 billion. Those sales fulfill almost half of his pledge on Twitter to sell 10% of his stake in Tesla.\nMusk began selling shares last week after floating the idea in aTwitter poll.\nWith electric-car makers increasingly in demand on Wall Street, Tesla's stock has surged more than 150% in the past 12 months.\n\"There's still plenty of buying interest because I still think ultimately investors are viewing this as a phase and viewing pullbacks as an opportunity,\" said Craig Erlam, senior market economist at OANDA.\n\"If you ask me where the share price is going to be six months from now, 12 months from now? I'd say it's more likely to be 20% higher than 20% lower.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":430,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607252295,"gmtCreate":1639551364321,"gmtModify":1639551395541,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"thanks","listText":"thanks","text":"thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607252295","repostId":"1127951705","repostType":2,"repost":{"id":"1127951705","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1639527737,"share":"https://www.laohu8.com/m/news/1127951705?lang=&edition=full","pubTime":"2021-12-15 08:22","market":"us","language":"en","title":"Over 25% Of Nio Option Flows Are Expiring Friday: Will It Bounce?","url":"https://stock-news.laohu8.com/highlight/detail?id=1127951705","media":"Benzinga","summary":"What Happened:Shares of NIO Inc lost 4% Tuesday as many U.S. and Asian stocks fell due to omicron CO","content":"<p><b>What Happened:</b>Shares of&nbsp;<b>NIO Inc</b>&nbsp;lost 4% Tuesday&nbsp;as many U.S. and Asian stocks fell due to omicron COVID-19 variant concerns.</p>\n<p>The stock is approaching a major support level around $30 that has held since October of 2020.&nbsp;Looking at the option flows on the day, there are over 148,000 calls and 71,000 puts, so two out of every three&nbsp;options&nbsp;on the day are calls (image below).</p>\n<p>Prior to Tuesday's trading, there were approximately 1.8 million calls and 1.6 million puts in NIO for a total of 3.48 million options.</p>\n<p><img src=\"https://static.tigerbbs.com/1829707a572d0f5331bc22fb8bb77d2e\" tg-width=\"1023\" tg-height=\"279\" width=\"100%\" height=\"auto\"></p>\n<p>This means that the option flows for Tuesday&nbsp;represent about 7% of the total options, which is solid considering the FOMC meeting on Wednesday, Dec. 15 is putting a damper on flows.</p>\n<p><b>Why It Matters:</b>Generally traders do not make aggressive bets ahead of a&nbsp;FOMC, meeting, especially the last one of the year, which could set the tone for trading in 2022.</p>\n<p>Of the approximately 219,000 options traded today, only about 60,000 of them are short dated (expiring Friday, Dec. 17), which means the majority of flows are forward looking beyond the FOMC and monthly op-ex.</p>\n<p>The next largest option expiry by volume is the Jan.&nbsp;21 op-ex, which means a strong amount of traders are taking bullish bets on Nio&nbsp;into next year.</p>\n<p><b>What's Next:</b>Looking at the option chain for the Jan. 21 expiry next year, the largest strikes by volume are concentrated between the $35 and $40 strikes (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/747fa367be175f2627d9a91fd7542fac\" tg-width=\"1117\" tg-height=\"399\" width=\"100%\" height=\"auto\"></p>\n<p>Meanwhile, the largest strikes by open interest are the $40 and $45 strikes, which shows a fair amount of interest for a bounce off support and a move back up into the $40s.</p>\n<p>It should be noted the option market is currently pricing in a 14% probability NIO closes at or above $40 by the January op-ex next year, so it's currently a lower probability event.</p>\n<p>But if the $30 level can hold for this week&nbsp;and there is no hawkishness out of the Fed for the FOMC on Dec. 15, then equities might get a Christmas rally to end the year, as the bearish pressure leading into the FOMC could subside.</p>\n<p>On the other hand, if the stock closes below the $30 level on a weekly closing basis, then the next support does not come in until&nbsp;around $25.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Over 25% Of Nio Option Flows Are Expiring Friday: Will It Bounce?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOver 25% Of Nio Option Flows Are Expiring Friday: Will It Bounce?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-15 08:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>What Happened:</b>Shares of&nbsp;<b>NIO Inc</b>&nbsp;lost 4% Tuesday&nbsp;as many U.S. and Asian stocks fell due to omicron COVID-19 variant concerns.</p>\n<p>The stock is approaching a major support level around $30 that has held since October of 2020.&nbsp;Looking at the option flows on the day, there are over 148,000 calls and 71,000 puts, so two out of every three&nbsp;options&nbsp;on the day are calls (image below).</p>\n<p>Prior to Tuesday's trading, there were approximately 1.8 million calls and 1.6 million puts in NIO for a total of 3.48 million options.</p>\n<p><img src=\"https://static.tigerbbs.com/1829707a572d0f5331bc22fb8bb77d2e\" tg-width=\"1023\" tg-height=\"279\" width=\"100%\" height=\"auto\"></p>\n<p>This means that the option flows for Tuesday&nbsp;represent about 7% of the total options, which is solid considering the FOMC meeting on Wednesday, Dec. 15 is putting a damper on flows.</p>\n<p><b>Why It Matters:</b>Generally traders do not make aggressive bets ahead of a&nbsp;FOMC, meeting, especially the last one of the year, which could set the tone for trading in 2022.</p>\n<p>Of the approximately 219,000 options traded today, only about 60,000 of them are short dated (expiring Friday, Dec. 17), which means the majority of flows are forward looking beyond the FOMC and monthly op-ex.</p>\n<p>The next largest option expiry by volume is the Jan.&nbsp;21 op-ex, which means a strong amount of traders are taking bullish bets on Nio&nbsp;into next year.</p>\n<p><b>What's Next:</b>Looking at the option chain for the Jan. 21 expiry next year, the largest strikes by volume are concentrated between the $35 and $40 strikes (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/747fa367be175f2627d9a91fd7542fac\" tg-width=\"1117\" tg-height=\"399\" width=\"100%\" height=\"auto\"></p>\n<p>Meanwhile, the largest strikes by open interest are the $40 and $45 strikes, which shows a fair amount of interest for a bounce off support and a move back up into the $40s.</p>\n<p>It should be noted the option market is currently pricing in a 14% probability NIO closes at or above $40 by the January op-ex next year, so it's currently a lower probability event.</p>\n<p>But if the $30 level can hold for this week&nbsp;and there is no hawkishness out of the Fed for the FOMC on Dec. 15, then equities might get a Christmas rally to end the year, as the bearish pressure leading into the FOMC could subside.</p>\n<p>On the other hand, if the stock closes below the $30 level on a weekly closing basis, then the next support does not come in until&nbsp;around $25.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127951705","content_text":"What Happened:Shares of NIO Inc lost 4% Tuesday as many U.S. and Asian stocks fell due to omicron COVID-19 variant concerns.\nThe stock is approaching a major support level around $30 that has held since October of 2020. Looking at the option flows on the day, there are over 148,000 calls and 71,000 puts, so two out of every three options on the day are calls (image below).\nPrior to Tuesday's trading, there were approximately 1.8 million calls and 1.6 million puts in NIO for a total of 3.48 million options.\n\nThis means that the option flows for Tuesday represent about 7% of the total options, which is solid considering the FOMC meeting on Wednesday, Dec. 15 is putting a damper on flows.\nWhy It Matters:Generally traders do not make aggressive bets ahead of a FOMC, meeting, especially the last one of the year, which could set the tone for trading in 2022.\nOf the approximately 219,000 options traded today, only about 60,000 of them are short dated (expiring Friday, Dec. 17), which means the majority of flows are forward looking beyond the FOMC and monthly op-ex.\nThe next largest option expiry by volume is the Jan. 21 op-ex, which means a strong amount of traders are taking bullish bets on Nio into next year.\nWhat's Next:Looking at the option chain for the Jan. 21 expiry next year, the largest strikes by volume are concentrated between the $35 and $40 strikes (image below).\n\nMeanwhile, the largest strikes by open interest are the $40 and $45 strikes, which shows a fair amount of interest for a bounce off support and a move back up into the $40s.\nIt should be noted the option market is currently pricing in a 14% probability NIO closes at or above $40 by the January op-ex next year, so it's currently a lower probability event.\nBut if the $30 level can hold for this week and there is no hawkishness out of the Fed for the FOMC on Dec. 15, then equities might get a Christmas rally to end the year, as the bearish pressure leading into the FOMC could subside.\nOn the other hand, if the stock closes below the $30 level on a weekly closing basis, then the next support does not come in until around $25.","news_type":1},"isVote":1,"tweetType":1,"viewCount":697,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872949266,"gmtCreate":1637405323787,"gmtModify":1637405325999,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"wa...&nbsp;","listText":"wa...&nbsp;","text":"wa...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872949266","repostId":"2184840345","repostType":2,"isVote":1,"tweetType":1,"viewCount":951,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878303481,"gmtCreate":1637144527827,"gmtModify":1637144527827,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"thanks!!","listText":"thanks!!","text":"thanks!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878303481","repostId":"2184511834","repostType":2,"isVote":1,"tweetType":1,"viewCount":110,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871634396,"gmtCreate":1637061979187,"gmtModify":1637061979250,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"oh no....","listText":"oh no....","text":"oh no....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871634396","repostId":"2183007300","repostType":2,"repost":{"id":"2183007300","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637061660,"share":"https://www.laohu8.com/m/news/2183007300?lang=&edition=full","pubTime":"2021-11-16 19:21","market":"us","language":"en","title":"Tesla stock falls 1.4% premarket, heads toward 4th-straight loss and 7th loss in 8 days","url":"https://stock-news.laohu8.com/highlight/detail?id=2183007300","media":"Dow Jones","summary":"MW Tesla stock falls 1.4% premarket, heads toward 4th-straight loss and 7th loss in 8 days\n\n\n \n\n\n$(E","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Tesla stock falls 1.4% premarket, heads toward 4th-straight loss and 7th loss in 8 days\n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  November 16, 2021 06:21 ET (11:21 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla stock falls 1.4% premarket, heads toward 4th-straight loss and 7th loss in 8 days</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla stock falls 1.4% premarket, heads toward 4th-straight loss and 7th loss in 8 days\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-16 19:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Tesla stock falls 1.4% premarket, heads toward 4th-straight loss and 7th loss in 8 days\n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  November 16, 2021 06:21 ET (11:21 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2183007300","content_text":"MW Tesla stock falls 1.4% premarket, heads toward 4th-straight loss and 7th loss in 8 days\n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  November 16, 2021 06:21 ET (11:21 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":534,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873709135,"gmtCreate":1636983414200,"gmtModify":1636983414200,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"yeah!!","listText":"yeah!!","text":"yeah!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873709135","repostId":"2183022451","repostType":2,"isVote":1,"tweetType":1,"viewCount":452,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873541663,"gmtCreate":1636967682367,"gmtModify":1636967682367,"author":{"id":"4098771492575270","authorId":"4098771492575270","name":"Armda","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098771492575270","authorIdStr":"4098771492575270"},"themes":[],"htmlText":"yeah","listText":"yeah","text":"yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873541663","repostId":"2183286630","repostType":2,"isVote":1,"tweetType":1,"viewCount":279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}